<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">NPJ Syst Biol Appl</journal-id><journal-id journal-id-type="iso-abbrev">NPJ Syst Biol Appl</journal-id><journal-id journal-id-type="pmc-domain-id">3172</journal-id><journal-id journal-id-type="pmc-domain">npjsba</journal-id><journal-title-group><journal-title>NPJ Systems Biology and Applications</journal-title></journal-title-group><issn pub-type="epub">2056-7189</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10948391</article-id><article-id pub-id-type="pmcid-ver">PMC10948391.1</article-id><article-id pub-id-type="pmcaid">10948391</article-id><article-id pub-id-type="pmcaiid">10948391</article-id><article-id pub-id-type="pmid">38499572</article-id><article-id pub-id-type="doi">10.1038/s41540-024-00355-3</article-id><article-id pub-id-type="publisher-id">355</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Making drugs from T cells: The quantitative pharmacology of engineered T cell therapeutics</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-9601-1913</contrib-id><name name-style="western"><surname>Kirouac</surname><given-names initials="DC">Daniel C.</given-names></name><address><email>daniel.kirouac@ubc.ca</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-2368-5658</contrib-id><name name-style="western"><surname>Zmurchok</surname><given-names initials="C">Cole</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Morris</surname><given-names initials="D">Denise</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label>Notch Therapeutics, Vancouver, BC Canada </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03rmrcq20</institution-id><institution-id institution-id-type="GRID">grid.17091.3e</institution-id><institution-id institution-id-type="ISNI">0000 0001 2288 9830</institution-id><institution>The University of British Columbia, </institution><institution>School of Biomedical Engineering, </institution></institution-wrap>Vancouver, BC Canada </aff><aff id="Aff3"><label>3</label>Emerald City Pharma Consulting, Blaine, WA USA </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04j2hh758</institution-id><institution-id institution-id-type="GRID">grid.512372.0</institution-id><institution>Present Address: Metrum Research Group, </institution></institution-wrap>Tariffville, CT USA </aff></contrib-group><pub-date pub-type="epub"><day>18</day><month>3</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>10</volume><issue-id pub-id-type="pmc-issue-id">452702</issue-id><elocation-id>31</elocation-id><history><date date-type="received"><day>17</day><month>11</month><year>2023</year></date><date date-type="accepted"><day>26</day><month>2</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>18</day><month>03</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>19</day><month>03</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-03-20 11:25:16.343"><day>20</day><month>03</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2024</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41540_2024_Article_355.pdf"/><abstract id="Abs1"><p id="Par1">Engineered T cells have emerged as highly effective treatments for hematological cancers. Hundreds of clinical programs are underway in efforts to expand the efficacy, safety, and applications of this immuno-therapeutic modality. A primary challenge in developing these &#8220;living drugs&#8221; is the complexity of their pharmacology, as the drug product proliferates, differentiates, traffics between tissues, and evolves through interactions with patient immune systems. Using publicly available clinical data from Chimeric Antigen Receptor (CAR) T cells, we demonstrate how mathematical models can be used to quantify the relationships between product characteristics, patient physiology, pharmacokinetics and clinical outcomes. As scientists work to develop next-generation cell therapy products, mathematical models will be integral for contextualizing data and facilitating the translation of product designs to clinical strategy.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Cancer</kwd><kwd>Computer modelling</kwd><kwd>Pharmacokinetics</kwd><kwd>Immunology</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Limited 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2">Genetically engineered T cells have proven highly efficacious in treating B cell malignancies, generating durable tumor responses and even cures with a single dose. Six chimeric antigen receptor T cell (CAR-T) therapies have been approved by the FDA since 2017, targeting either CD19 or B Cell Maturation Antigen (BCMA). Efficacy varies by indication and product, but complete response rates typically exceed 50% and extend beyond a year<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. This is remarkable for treatment-refractory cancers and for patients who have progressed on multiple lines of chemotherapy. These results have galvanized the field, and hundreds of CAR- and TCR-engineered T-cell therapies are now in clinical development for the treatment of a range of cancers and immune disorders<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. The ability to engineer and deliver targeted cellular immunity offers the potential to tackle diseases with limited treatment options<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>.</p><p id="Par3">Currently, all approved CAR-T products are autologous (derived from patient blood draws), though allogeneic (healthy donor- or stem cell-derived) products are in clinical development. T cells are isolated from a patient&#8217;s blood, modified using lentiviral vectors or other synthetic biology approaches, expanded using cytokine cocktails and CD3-stimultion ex vivo, then infused back into patients. While effective, these &#8216;living drugs&#8217; make unruly therapeutics. The infused T cell compositions actively traffic between tissues, proliferate, differentiate, and interact with patient immune systems in complex and poorly understood ways. If engineered T cells are to fulfill their promise as a groundbreaking therapeutic platform, it is critical to understand their unique pharmacology, and further leverage this understanding to improve product design, treatment regimens, and clinical outcomes.</p><p id="Par4">Developing a novel therapeutic agent from discovery through pre-clinical and clinical stages requires a quantitative understanding of <italic toggle="yes">what the body does to the drug</italic> (pharmacokinetics) and <italic toggle="yes">what the drug does to the body</italic> (pharmacodynamics). This involves the use of mathematical and statistical models to characterize absorption, distribution, routes of elimination, and the relationship between drug exposure and pharmacological activity. Pharmacokinetic-Pharmacodynamic (PKPD) modelling principles were first introduced in the &#8220;age of small molecules&#8221;<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>. The original mathematical models were highly empirical; they described the pharmacokinetics and exposure-response relationships in patient populations without regard for underlying biological mechanisms. These principles were translated to antibody therapeutics as they emerged in the 1980s, and now to the burgeoning varieties of engineered biotherapeutics<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>. As therapeutic agents have become more complex, the modelling approaches used to characterize their behavior have as well. State-of-the art methodologies now incorporate mechanistically detailed descriptions of ligand-receptor interactions (mechanistic-PKPD)<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>, the physicochemistry and physiology affecting exposure and tissue distribution (physiologically-based PK)<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>, and the cellular biochemistry mediating efficacy and toxicity (systems pharmacology)<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>.</p><p id="Par5">Although model-informed drug development has been widely adopted by both industry and regulatory bodies<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>, integration of these quantitative methods into the nascent CAR-T field has been sporadic. While the underlying biology of T-cell therapies may be complex, we believe the insights from mathematical model-based analyses can facilitate cell therapy research and clinical development.</p><p id="Par6">While there are hundreds of review articles detailing the molecular biology of T cells and advances in chimeric antigen receptor T cell (CAR-T) engineering and clinical data (e.g.<sup><xref ref-type="bibr" rid="CR1">1</xref>&#8211;<xref ref-type="bibr" rid="CR3">3</xref></sup>), there are only a limited number of articles highlighting mathematical approaches which have been employed to describe the pharmacology of CAR-Ts<sup><xref ref-type="bibr" rid="CR10">10</xref>&#8211;<xref ref-type="bibr" rid="CR14">14</xref></sup>. The latter are technical pieces written for pharmacometricians rather than biologists or clinicians, and do not tangibly relate fundamental concepts in quantitative pharmacology (bioavailability, distribution, and clearance) to emerging clinical data, nor how CAR-T product design and patient physiology can modulate key pharmacological parameters. Herein, we take a novel approach to connect these concepts, using simulations of published mathematical models for demonstrative purposes.</p><p id="Par7">We first outline the principles of pharmacology, their application to adoptive T-cell therapy, and the fundamental challenges faced in clinical development of these agents. We then use model simulations to study the effects of cellular heterogeneity and product-intrinsic variance, biodistribution, lymphodepletion response, and allogeneic elimination on CAR-T pharmacokinetics. Finally, we provide perspectives on how data from in vitro functional assays can be integrated with CRISPR-screens and single-cell sequencing to inform clinical development.</p></sec><sec id="Sec2"><title>Results &amp; Discussion</title><sec id="Sec3"><title>Principles of pharmacology: Pharmacokinetics and Pharmacodynamics</title><p id="Par8">Pharmacokinetic (PK) curves describe the time-course of drug concentration following administration (Fig. <xref rid="Fig1" ref-type="fig">1A</xref>). There are a few key exposure metrics used to quantify these time courses. The maximal concentration reached following administration (<italic toggle="yes">Cmax)</italic>, the time at which this occurs (<italic toggle="yes">tmax)</italic>, and the area under the concentration-time curve (<italic toggle="yes">AUC</italic>). These parameters depend upon the dose, bioavailability of the compound, and physiological mechanisms mediating distribution and elimination. Pharmacodynamics (PD) describes the onset, intensity, and duration of a drug response (efficacious or adverse) and how it relates to the concentration of the drug at the site of action.<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><title>Pharmacology and living drugs.</title><p>Pharmacokinetic plots (<bold>A</bold>) represent drug concentration over time following administration. <italic toggle="yes">Cmax</italic> (maximal concentration), <italic toggle="yes">tmax</italic>, and <italic toggle="yes">AUC</italic> (concentration-time integral) are used to quantify these curves across populations. Exposure-response analyses (<bold>B</bold>) links drug exposure (e.g., <italic toggle="yes">Cmax</italic> or <italic toggle="yes">AUC</italic>) to drug efficacy and toxicity readouts, typically quantified using Hill-type equations. Separation of the efficacy and toxicity curves is referred to as the therapeutic index (TI). PKPD model simulations (<bold>C</bold>) are used to optimize dosing regimens (dose and schedule) which maximize efficacy while minimizing toxicity (each colored line represents a different dose). CAR-T pharmacokinetics (<bold>D</bold>) can be subdivided into four phases. Immediately following administration is a biodistribution phase, where circulating cell counts rapidly decline, typically to below the limit of quantification. This is followed by an expansion phase, where CAR-Ts proliferate for approximately 2 weeks up to a maximal expansion (<italic toggle="yes">Cmax</italic>), followed by a period of rapid contraction and then persistence (slow clearance). <bold>E</bold> The empirical population PK model of Kymriah simulated for 1000 virtual patients and represented via percentiles of inter-individual variability (IIV).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e320" position="float" orientation="portrait" xlink:href="41540_2024_355_Fig1_HTML.jpg"/></fig></p><p id="Par9">Exposure-response (ER) analyses (or pharmacokinetic-pharmacodynamic [PKPD] modeling) are used to relate metrics of drug exposure (e.g., concentration or AUC) to measures of both efficacy and toxicity (Fig. <xref rid="Fig1" ref-type="fig">1B</xref>). The variance in exposure necessary to build this relationship can be achieved either from dose-ranging studies and/or by utilizing the observed variability in pharmacokinetic parameters across a patient population. The window between efficacy vs. toxicity is referred to as the therapeutic index and can be quantified by examining the estimated <italic toggle="yes">EC</italic><sub><italic toggle="yes">50</italic></sub> values. Ideally, one would like to have as wide a therapeutic index as possible. However, what is considered acceptable depends on the indication. For example, a much narrower therapeutic index would be acceptable for a cancer treatment compared to over-the-counter pain relief.</p><p id="Par10">As a drug advances through development, our understanding of the pharmacokinetics, exposure-response relationships, and relevant covariates (patient and disease characteristics) evolves. The end goal of PKPD modelling is typically to design an optimal dosing regimen which maximizes efficacy while minimizing toxicity across the target population (Fig. <xref rid="Fig1" ref-type="fig">1C</xref>). So how do these foundational principles apply to CAR-T cell therapies?</p></sec><sec id="Sec4"><title>Pharmacology of T cell therapy</title><p id="Par11">The pharmacokinetics of adoptive T cells can be evaluated by blood sampling, either via flow cytometry or PCR-based detection of the CAR transgene. Experience to date with CAR-Ts has shown the behavior, often referred to as <italic toggle="yes">cellular kinetics</italic>, can be segregated into four phases (Fig. <xref rid="Fig1" ref-type="fig">1D</xref>).</p><p id="Par12">The first is <italic toggle="yes">biodistribution</italic>. Following infusion, administered T cells rapidly disappear from circulation, and blood concentration will drop by orders of magnitude within a few days<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>. The kinetics of this process are poorly characterized, as the dense time sampling required over the first few hours following administration is rarely performed or reported. Likely the cells actively traffic from circulation into tissues, but the interplay between the cell characteristics, target and anatomic pathology, and the clinical implications remain unknown. Notably, the same phenomenon has been observed for other T cell activating therapies such as IL15<sup><xref ref-type="bibr" rid="CR16">16</xref></sup> and CD3-bispecific engagers<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. The biodistribution phase thus appears to be a feature of T cell activation rather than specific to CAR-T dosing.</p><p id="Par13">The subsequent phases are <italic toggle="yes">expansion</italic>, followed by <italic toggle="yes">contraction</italic> and then <italic toggle="yes">persistence</italic>. Cell numbers in the blood rapidly expand for approximately two weeks as the cells encounter antigen and proliferate. After reaching <italic toggle="yes">Cmax</italic>, circulating cell numbers begin to rapidly <italic toggle="yes">contract</italic>. As antigen is cleared, active effector T cells either die or convert to long-term memory T cells<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. This rapid contraction phase precedes a period of long-term <italic toggle="yes">persistence</italic> or gradual decline, which can last a decade or more<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. While comprising only a small fraction of circulating T cells (&lt;0.5%), long-term persistent CAR-T cells acquire a distinct phenotype and transcriptional features indicative of antigen stimulation, driven by CD19/BCMA-expression on both healthy and cancerous B cells. Presumably, this population responds to remanent tumor cells as they arise thereby maintaining durable responses<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>.</p><p id="Par14">While the biology underlying these phases may be unclear, empirical mathematical models have been used to quantify the cellular kinetics of CAR-Ts from clinical and pre-clinical studies<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>. The first CAR-T population pharmacokinetic model was developed by Novartis<sup><xref ref-type="bibr" rid="CR21">21</xref></sup> and included in the Biologics License Application (BLA) for the CD19-targeted CAR-T Kymriah (tisagenlecleucel)<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>. It is empirical in that the model describes the typical shape of the curves using six parameters, without specifying mechanisms mediating the kinetic phase transitions. Both the population average and variance for each parameter are estimated, thereby converting the pharmacokinetic data into a vector of 12 numbers (see Fig. <xref rid="Fig1" ref-type="fig">1E</xref>). The equations and parameter estimates then serve as a computational representation by which new data can be benchmarked and are used for this purpose by FDA reviewers<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>.</p></sec><sec id="Sec5"><title>Drug development challenges emanating from CAR-T pharmacology</title><sec id="Sec6"><title>Narrow Therapeutic Index</title><p id="Par15">Exposure-response analyses for multiple CAR-Ts in different indications reveal that both <italic toggle="yes">AUC</italic> and <italic toggle="yes">Cmax</italic> are predictive of response and toxicity (primarily cytokine release syndrome [CRS]). Patients that fall on the high end of pharmacokinetic exposure are likely to have robust tumor shrinkage, but also experience grade 3/4 CRS with little to no therapeutic index (e.g., the dose vs. response and CRS curves overlap for Abecma, a BCMA-targeted CAR-T approved for the treatment of multiple myeloma; Fig. <xref rid="Fig2" ref-type="fig">2A</xref><bold>)</bold>. This tight correlation points to important biology &#8211; the same mechanisms underlying efficacy also mediate toxicity. Activation of circulating T cells and systemic production of inflammatory cytokines is required for tumor clearance, but these processes also cause CRS. Dose fractionation may be an approach to separate CRS from efficacy, as fractionation has been an effective strategy to manage similar toxicities encountered with bispecific T-cell engagers<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>. Preliminary data from a small number of clinical CAR-T trials seem to support this idea<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>.<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><title>Drug development challenges emanating from CAR-T pharmacology.</title><p><bold>A</bold> The exposure-response model reported for Abecma (a BCMA-targeted CAR-T) simulated using reported parameters for efficacy (response rate) and toxicity (Cytokine release syndrome requiring anti-IL6 tocilizumab or steroids) as functions of 28-day <italic toggle="yes">AUC</italic>. <bold>B</bold> Distribution of 28-day <italic toggle="yes">AUC</italic> from Kymriah population simulations over a two-order magnitude dose-range. IIV represented for 95, 80 and 50 percentiles as in Fig. <xref rid="Fig1" ref-type="fig">1E</xref>. <bold>C</bold> Correlation between <italic toggle="yes">Cmax</italic> and <italic toggle="yes">AUC</italic> from the Kymriah dose range simulations in <bold>B</bold>. <bold>D</bold> Simulations over a 10-fold range of maximal cell expansion (<italic toggle="yes">Cmax</italic>) effect size vs. a 10-fold range in log-variance were performed. At each point in the grid, minimum sample size (minimum N) requirements for detecting a statistical difference in 28-day log-<italic toggle="yes">AUC</italic> as compared to control were computed (two sample t-test, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05 and 80% power).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e492" position="float" orientation="portrait" xlink:href="41540_2024_355_Fig2_HTML.jpg"/></fig></p></sec><sec id="Sec7"><title>High interpatient variability</title><p id="Par16">Inter-patient variability in exposure (both <italic toggle="yes">Cmax</italic> and <italic toggle="yes">AUC</italic>) is much wider for CAR-Ts than small molecules or biologics. &#8220;Highly variable drugs&#8221; are defined by the FDA as those for which inter-subject variance (%CV) in exposure is greater than 30%<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>. Highly variable drugs are usually considered an exception and problematic for both developers and regulators. For approved CAR-Ts, PK variance typically spans three orders of magnitude (Fig. <xref rid="Fig1" ref-type="fig">1E</xref>), which would terminate a typical drug program. In addition, for small molecules or biologics, drug developers hope to see a clear and consistent relationship (e.g., doubling the dose should correspondingly double the exposure). For CAR-Ts this relationship is often obscured by the high inter-patient variability (Fig. <xref rid="Fig2" ref-type="fig">2B</xref>). In other words, inter-patient variance in exposure typically exceeds the range of dose-dependent effect sizes, necessitating many more patients than are typically enrolled in an early clinical study to detect a statistically significant relationship. Exposure is primarily driven by variance in maximal cell expansion (<italic toggle="yes">Cmax</italic>) rather than dose (Fig. <xref rid="Fig2" ref-type="fig">2C</xref>). This result is not surprising since CAR-T expansion is antigen-dependent<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR28">28</xref></sup> and is corroborated by clinical observations<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>. Given the weak correlation between dose and exposure, CAR-T therapies cannot be dose-optimized as expected for other therapeutic modalities<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>. Thus, exposure-response analyses are useful for retrospective analyses but have little use in prospective decision making.</p><p id="Par17">Insights into the sources of this variance can be gleaned from data as well as theory. In contrast to clinical studies, dose-exposure relationships for CAR Ts are often observed in pre-clinical in vivo studies<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>. These experiments are typically performed with a single batch of starting material and use genetically homogenous mice with uniform tumor xenografts. That is, pre-clinical studies actively minimize variability in both starting material and &#8216;patient&#8217; populations. Systematic meta-analyses of clinical endpoints has revealed that BCMA-targeted products have less variance and a tighter dose-exposure relationships than CD19-targeted products<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>. These observations indicate that some of the pharmacokinetic variance may be attributable to differences in cancer biology, tumor burden and antigen expression patterns, while the remaining may be attributable to differences in T cell starting material, CAR constructs, or other complex, poorly defined physiological variables.</p><p id="Par18">The wide variability in exposure creates significant challenges for clinical development. Consider the recent FDA guidance on implementation of &#8216;umbrella trials&#8217; for cell therapy products<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>. Umbrella designs enable the testing of multiple product iterations under a single, multi-arm trial with a single master-protocol and Investigational New Drug (IND) submission. Under this framework, cell therapy developers could test alternate product designs (gene editing strategies, CAR variants, manufacturing protocols, etc.) head-to-head in a clinical setting. However, success is contingent on the ability to make relatively rapid decisions on the clinical benefit of alternative treatment arms, which in turn depends on the treatment effect size relative to the population variance. Observing a statistically significant treatment effect will be challenging for CAR-T products that exhibit large variance. To demonstrate this, we implemented simulations of the Kymriah population pharmacokinetic model as a benchmark CAR-T. Specifically, we used this model to assess how many patients per arm are necessary to detect a statistical difference in tumor response, using simulated exposures (<italic toggle="yes">AUC-28</italic>) as a surrogate (Fig. <xref rid="Fig2" ref-type="fig">2D</xref>). With 10 patients included in each arm of the trial and the same PK variance as Kymriah, observing a statistically significant effect of an alternate product design would require a 500% effect size (5-fold increase compared to control). Such large effect sizes seem unlikely under the guise of an umbrella trial. A more reasonable 200% effect size would necessitate 40 patients per treatment arm. However, if the PK variance was substantially reduced, the required number of enrolled patients would be much lower. Considering that pivotal clinical trials costs upward of $40,000 USD per patient<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>, and would be substantially higher for early cell therapy studies. Reducing PK variability is thus a pre-requisite for making multi-arm umbrella trials and iterative clinical development both practically feasible and financially viable for CAR-T therapies.</p></sec></sec><sec id="Sec8"><title>Predictive biomarkers of CAR-T product quality and clinical outcomes</title><p id="Par19">Both <italic toggle="yes">Cmax</italic><sup><xref ref-type="bibr" rid="CR35">35</xref></sup> and immunophenotype of circulating CAR-Ts following expansion are predictive of patient response. That is, patients with robust and durable tumor responses are more likely to have PK profiles in the top quartile of the distribution (Figs. <xref rid="Fig1" ref-type="fig">1</xref>E and <xref rid="Fig2" ref-type="fig">2A</xref>), and circulating CAR-Ts comprised of larger proportions of effector rather than exhausted and regulatory T cells<sup><xref ref-type="bibr" rid="CR36">36</xref>&#8211;<xref ref-type="bibr" rid="CR38">38</xref></sup>. While a predictive model of response based on an early clinical readout (e.g., a two-week blood draw) could be informative for subsequent patient care, it would be much more valuable to accurately predict outcomes and modify the treatment regimen before initiation (ideally prior to lymphodepletion). Current release criteria for CAR-T products are CD4/CD8 expression, CAR expression, cell viability and cell number. However, none of these metrics are predictive of clinical outcomes<sup><xref ref-type="bibr" rid="CR39">39</xref>&#8211;<xref ref-type="bibr" rid="CR41">41</xref></sup> and there are anecdotal reports of CAR-T products which failed release testing yet yielded robust and durable responses<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>. Therefore, quantitative, robust metrics relating pre-infusion product characteristics (e.g., T cell subpopulation phenotyping, cytokine-release assays, transcriptome profiles) to clinical outcomes are needed for both batch release criteria and for process optimization studies.</p><p id="Par20">The frequency of memory vs. exhausted T cell sub-populations has been correlated with response in multiple clinical studies<sup><xref ref-type="bibr" rid="CR43">43</xref>,<xref ref-type="bibr" rid="CR44">44</xref></sup>. However, the specific markers and flow cytometry gating strategies used to evaluate this are inconsistent and the phenotype-response correlations are generally low. The correlations thus do not robustly translate between clinical studies with differing patient populations and CAR-T manufacturing strategies<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>. In vitro cytokine-release assays have also been shown to correlate with response<sup><xref ref-type="bibr" rid="CR46">46</xref></sup>, albeit with limited study sizes and highly inconsistent metrics. A series of publications have reported transcriptome profiles of pre-infusion CAR-T products matched with clinical outcomes<sup><xref ref-type="bibr" rid="CR38">38</xref>,<xref ref-type="bibr" rid="CR47">47</xref>,<xref ref-type="bibr" rid="CR48">48</xref></sup>. In theory, these types of datasets are amenable to unbiased, machine learning approaches to identify predictive biomarkers of response. Yet, they are limited by the &#8220;<italic toggle="yes">large P, small N problem</italic>&#8221;. The sample numbers (<italic toggle="yes">N</italic>&#8201;&lt;&#8201;30) are too small for unbiased statistical models to extract predictive features from the large number of measurements (<italic toggle="yes">P</italic>&#8201;~&#8201;20,000 genes). Intelligent feature engineering strategies are thus required to pre-process the data. Gene set enrichment analyses, for example, have identified transcriptome signatures correlated with response from such studies; signatures for memory, exhausted, and NKT-cells, as well as inflammatory signaling<sup><xref ref-type="bibr" rid="CR48">48</xref></sup>. These are however correlations observed in single studies, rather than predictive models. By combining multiple transcriptome datasets, we were able to train a machine learning classifier using a panel of 28 gene signatures that is highly predictive of response in different indications<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>. Clinical outcomes thus emanate in part from characteristics of the infused cell population, and these attributes, to varying extents, were shared between clinical studies, diseases, and CAR-T products. As publicly available transcriptome data accumulates (e.g.<sup><xref ref-type="bibr" rid="CR49">49</xref></sup>), individual studies can be combined for integrated analysis and refinement of predictive classifiers.</p></sec><sec id="Sec9"><title>Using mathematical models to extract product- and patient-intrinsic factors impacting CAR-T pharmacology and clinical outcomes</title><sec id="Sec10"><title>Memory cell proliferative capacity and product-intrinsic variance</title><p id="Par21">Despite the extensive literature on mathematical models of T cell-tumor interactions<sup><xref ref-type="bibr" rid="CR50">50</xref></sup>, only a few mechanism-based models have been trained using clinical CAR-T PKPD data<sup><xref ref-type="bibr" rid="CR51">51</xref>,<xref ref-type="bibr" rid="CR52">52</xref></sup>. Parameterizing such models with data from responders and non-responders can identify explanatory variables underlying response and grounded in established biology. Using data from a study of Kymriah in chronic lymphocytic leukemia (CLL)<sup><xref ref-type="bibr" rid="CR44">44</xref></sup> and a mechanism-based model of CAR-T cell-tumor antigen interactions, we found the turnover rate of memory cell sub-populations in the CAR-T product to be a key differentiator of response, while memory cell frequency in the infused product was not<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>. This finding was confirmed using single cell transcriptomes from a handful of unrelated clinical studies; CAR-T products resulting in poor clinical response contained memory sub-populations with transcriptional features of functional exhaustion, despite similar immunophenotypes. A subsequent paper reached concordant conclusions i.e. cell-intrinsic functional measures (proliferative capacity and cytotoxic potency) rather than immunophenotypes underly differences in response<sup><xref ref-type="bibr" rid="CR53">53</xref></sup>. Prospective simulations of the model reveal memory cell proliferation rate as a sufficient explanatory variable underlying exposure and response (Fig. <xref rid="Fig3" ref-type="fig">3</xref>).<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><title>Memory cell proliferation rate can explain pharmacokinetic differences underlying response.</title><p><bold>A</bold> The population pharmacokinetic model of Kymriah<sup><xref ref-type="bibr" rid="CR21">21</xref></sup> simulated with alternate Cmax (fold expansion) parameters reported for responders vs. non-responders in B-ALL<sup><xref ref-type="bibr" rid="CR35">35</xref></sup>. <bold>B</bold> The mechanism-based PKPD model of Kymriah<sup><xref ref-type="bibr" rid="CR45">45</xref></sup> simulated over a range of memory cell proliferation rates, varying from 0.1 to 2-fold the estimated value.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e703" position="float" orientation="portrait" xlink:href="41540_2024_355_Fig3_HTML.jpg"/></fig></p><p id="Par22">Together, these results suggest that we could improve clinical outcomes if we could design CAR-T products containing memory cells with robust proliferative capacity. However, there are a few hinderances to doing so. First, proliferative capacity may be intrinsic to the patient-derived starting material. That is, autologous T cells may be of variable quality, which in turn determines quality of the resulting CAR-T product. Evidence for this lies in reports that healthy donor-derived T cells make more functionally active CAR-Ts with less batch-to-batch variability<sup><xref ref-type="bibr" rid="CR54">54</xref>,<xref ref-type="bibr" rid="CR55">55</xref></sup>, and the proliferation rate observed during the ex vivo expansion phase of manufacturing is predictive of clinical response<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>. Differences in T cell quality between disease states may additionally contribute to differences in clinical activity of expanded autologous products. For example, T cells from CLL patients appear more functionally exhausted compared to other lymphomas<sup><xref ref-type="bibr" rid="CR56">56</xref></sup>, and response rates to the derivative CAR-Ts are correspondingly lower. Second, there are no established protocols for consistently generating proliferative memory cells in culture. Although, shorter duration cultures with supportive cytokine cocktails seems to at least preserve memory cell function, improving clinical expansion, persistence, and activity<sup><xref ref-type="bibr" rid="CR57">57</xref>,<xref ref-type="bibr" rid="CR58">58</xref></sup>. Ultimately, the definition of product-intrinsic vs. patient-intrinsic is somewhat circular for autologous cell therapies. Patients from whom better CAR-T products are derived (enriched with highly proliferative memory cells) may have systemic cytokines or immune microenvironments supportive of such cells. The relative importance of cell- vs. patient-intrinsic variables are thus confounded, as the pharmacology depends on communication between the (patient-derived) product composition and patient physiology.</p></sec><sec id="Sec11"><title>T cell biodistribution effects on CAR-T pharmacology</title><p id="Par23">Although small molecules and biologics distribute throughout tissues following administration, blood is typically a reasonable surrogate of tissue concentration. However, this may not be the case for T cell therapies.</p><p id="Par24">Comparison of infused cell numbers vs. circulating CAR-T cell counts reveals the majority of cells infused are not present in the blood at first measurement (typically taken one to a few days after dosing). To directly compare between studies, we present a simple metric, termed the <italic toggle="yes">Expansion Ratio</italic> (<italic toggle="yes">Cmax</italic> &#215; Blood Volume/Cell dose), and report this for select clinical and preclinical studies (Table <xref rid="Tab1" ref-type="table">1</xref>). The <italic toggle="yes">Expansion Ratio</italic> estimates how many cells appear in circulation at the peak concentration per cell dosed. For preclinical studies this value is less than 1/100 and for clinical trials, expansion ratios &gt;1/10 seem to be a prerequisite for tumor response. Thus, even in responders with a high <italic toggle="yes">Cmax</italic> and multi-log expansion, circulating T cell counts typically just approach input cell numbers.<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Expansion ratios and dependent variables for select clinical and pre-clinical studies</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">CAR-T</th><th colspan="1" rowspan="1">Indication</th><th colspan="1" rowspan="1">Cell dose (cells)</th><th colspan="1" rowspan="1">Cmax (cell/&#181;L)</th><th colspan="1" rowspan="1">Expansion ratio</th><th colspan="1" rowspan="1">Reference</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">CD19 (Cy/Flu)</td><td colspan="1" rowspan="1">NHL</td><td colspan="1" rowspan="1">1.4 &#215; 10<sup>9</sup> *<sup>1</sup></td><td colspan="1" rowspan="1">500</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">Turtle<sup><xref ref-type="bibr" rid="CR29">29</xref></sup></td></tr><tr><td colspan="1" rowspan="1">CD19 (Cy)</td><td colspan="1" rowspan="1">NHL</td><td colspan="1" rowspan="1">1.4 &#215; 10<sup>9</sup> *<sup>1</sup></td><td colspan="1" rowspan="1">0.2</td><td colspan="1" rowspan="1">1/1400</td><td colspan="1" rowspan="1">Turtle<sup><xref ref-type="bibr" rid="CR29">29</xref></sup></td></tr><tr><td colspan="1" rowspan="1">CD19 (patient 1)</td><td colspan="1" rowspan="1">CLL: Responder</td><td colspan="1" rowspan="1">1.1 &#215; 10<sup>9</sup></td><td colspan="1" rowspan="1">20*<sup>2</sup></td><td colspan="1" rowspan="1">1/10</td><td colspan="1" rowspan="1">Kalos<sup><xref ref-type="bibr" rid="CR15">15</xref></sup></td></tr><tr><td colspan="1" rowspan="1">CD19 (patient 2)</td><td colspan="1" rowspan="1">CLL: Partial Resp.</td><td colspan="1" rowspan="1">5.8 &#215; 10<sup>8</sup></td><td colspan="1" rowspan="1">0.2*<sup>2</sup></td><td colspan="1" rowspan="1">1/600</td><td colspan="1" rowspan="1">Kalos<sup><xref ref-type="bibr" rid="CR15">15</xref></sup></td></tr><tr><td colspan="1" rowspan="1">CD19 (UCART19)</td><td colspan="1" rowspan="1">B-ALL: Responders</td><td colspan="1" rowspan="1">10<sup>8</sup>*<sup>3</sup></td><td colspan="1" rowspan="1">10&#8211;1000</td><td colspan="1" rowspan="1">1/2 - 50</td><td colspan="1" rowspan="1">Dupouy<sup><xref ref-type="bibr" rid="CR71">71</xref></sup></td></tr><tr><td colspan="1" rowspan="1">CD19 (UCART19)</td><td colspan="1" rowspan="1">B-ALL: Non-responders</td><td colspan="1" rowspan="1">10<sup>8</sup>*<sup>3</sup></td><td colspan="1" rowspan="1">&lt;1</td><td colspan="1" rowspan="1">&lt; 1/20</td><td colspan="1" rowspan="1">Dupouy<sup><xref ref-type="bibr" rid="CR71">71</xref></sup></td></tr><tr><td colspan="1" rowspan="1">CD19-CART</td><td colspan="1" rowspan="1">Lymphoma, mix</td><td colspan="1" rowspan="1">10<sup>8</sup>*<sup>4</sup></td><td colspan="1" rowspan="1">10&#8211;1000</td><td colspan="1" rowspan="1">1/3 - 70</td><td colspan="1" rowspan="1">Kochenderfer<sup><xref ref-type="bibr" rid="CR101">101</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Kymriah popPK 95%</td><td colspan="1" rowspan="1">B-ALL</td><td colspan="1" rowspan="1">10<sup>8</sup>*<sup>5</sup></td><td colspan="1" rowspan="1">300*<sup>6</sup></td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">Stein<sup><xref ref-type="bibr" rid="CR21">21</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Kymriah popPK 5%</td><td colspan="1" rowspan="1">B-ALL</td><td colspan="1" rowspan="1">10<sup>8</sup>*<sup>5</sup></td><td colspan="1" rowspan="1">10*<sup>6</sup></td><td colspan="1" rowspan="1">1/2</td><td colspan="1" rowspan="1">Stein<sup><xref ref-type="bibr" rid="CR21">21</xref></sup></td></tr><tr><td colspan="1" rowspan="1">BCMA 1-R2</td><td colspan="1" rowspan="1">Preclinical: MM.1&#8201;S</td><td colspan="1" rowspan="1">10<sup>7</sup></td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">1/250*<sup>7</sup></td><td colspan="1" rowspan="1">Sommer<sup><xref ref-type="bibr" rid="CR31">31</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Kymriah</td><td colspan="1" rowspan="1">Preclinical: NALM6</td><td colspan="1" rowspan="1">5 &#215; 10<sup>6</sup></td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">1/125*<sup>7</sup></td><td colspan="1" rowspan="1">Stein<sup><xref ref-type="bibr" rid="CR102">102</xref></sup></td></tr><tr><td colspan="1" rowspan="1">iPSC-gdT-CD19</td><td colspan="1" rowspan="1">Preclinical: NALM6</td><td colspan="1" rowspan="1">10<sup>7</sup></td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">1/2500*<sup>7</sup></td><td colspan="1" rowspan="1">Wallet<sup><xref ref-type="bibr" rid="CR103">103</xref></sup></td></tr></tbody></table><table-wrap-foot><p>*<sup>1</sup> 2 &#215; 10<sup>7</sup> cells/kg; assume 70&#8201;kg, 5&#8201;L blood volume.</p><p>*<sup>2</sup>reported as total cells; assume 5&#8201;L blood volume.</p><p>*<sup>3</sup>weighted average = 10<sup>8</sup>. DL1 (<italic toggle="yes">n</italic>&#8201;=&#8201;6)&#8201;=&#8201;6&#8201;&#215;&#8201;10<sup>6</sup>, DL2(<italic toggle="yes">n</italic>&#8201;=&#8201;12)&#8201;=&#8201;8 &#215; 10<sup>7</sup>, DL3(<italic toggle="yes">n</italic>&#8201;=&#8201;7)&#8201;=&#8201;2 &#215; 10<sup>8</sup>; no dose-response.</p><p>*<sup>4</sup>1&#8211;2 &#215; 10<sup>6</sup> cells/kg, assume 70&#8201;kg, 5&#8201;L blood volume.</p><p>*<sup>5</sup> median dose 3 &#215; 10<sup>6</sup> cells/kg for patients &#8804; 50&#8201;kg, and 10<sup>8</sup> for patients &gt; 50&#8201;kg.</p><p>*<sup>6</sup> scaled counts/ug DNA to cells/&#181;L using data from Kalos<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>.</p><p>*<sup>7</sup> Assume 2&#8201;mL total blood volume in mice.</p></table-wrap-foot></table-wrap></p><p id="Par25">A T cell biodistribution study performed in mice using unmodified, radio-labelled T cells found most of the infused cells rapidly accumulate in the lungs, spleen, liver, kidneys, and lymph nodes<sup><xref ref-type="bibr" rid="CR59">59</xref></sup>. Quantification of tissue vs. blood exposure revealed that for every cell detected in the blood, approximately 1000 are tissue-resident. A similar pattern was observed with CD19-CAR-Ts, with particularly rapid accumulation in lungs within the first day of infusion<sup><xref ref-type="bibr" rid="CR60">60</xref></sup>. It is perhaps not surprising that lung vasculature would be a physical bottleneck, and imaging studies have noted large multi-cellular aggregates of CAR-Ts and B cells trapped in the lung vascular network within 15&#8201;minutes after dosing<sup><xref ref-type="bibr" rid="CR61">61</xref></sup>. While human biodistribution data is not available, PBPK modelling predicts lung vasculature as the primary sink, accounting for &gt;99% of administered T cells<sup><xref ref-type="bibr" rid="CR62">62</xref></sup>.</p><p id="Par26">We explored the theoretical implications of this phenomenon using a minimal adaptation of our mechanistic CAR-T PKPD model<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>. By inclusion of a &#8216;tissue&#8217; compartment into which administered cells redistribute, PK profiles were simulated over a range of scenarios (Fig. <xref rid="Fig4" ref-type="fig">4</xref>). Rapid tissue biodistribution due to extravasation (trafficking of T cells from circulation into surrounding tissues) and the degree of cell &#8216;stickiness&#8217; (tissue extravasation vs. re-circulation rates) can have a dominant effect on exposure. For example, we can simulate a hypothetically effective CAR-T with robust expansion and <italic toggle="yes">Cmax</italic>, yet create an ineffective therapy that barely breaches the lower limit of quantification (LLQ) in circulation by simply increasing the tissue-stickiness.<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><title>T cell biodistribution may have profound effects on CAR-T pharmacokinetics.</title><p><bold>A</bold> Inclusion of a &#8216;tissue&#8217; compartment, with CAR-T cell distribution between blood and tissue described using two kinetic parameters &#8211; tissue extravasation (blue) vs. blood re-circulation (red). For simplicity, we assume CAR-T cells (T) interact with tumor cells (<bold>B</bold>) in the blood, while the tissue compartment acts as a sink. <bold>B</bold> Circulating CAR-T pharmacokinetics, simulated over a four-log range of blood:tissue distribution rates. Dashed line represents a theoretical LLQ.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1139" position="float" orientation="portrait" xlink:href="41540_2024_355_Fig4_HTML.jpg"/></fig></p><p id="Par27">Understanding where the administered cells accumulate, how much this varies between patients and populations, and whether these biodistribution patterns contribute to pharmacology and response seem to be important, yet relatively neglected, clinical problems. Whole-body fluorescence or radio-isotope imaging technologies could potentially be implemented to shed light on these unknowns<sup><xref ref-type="bibr" rid="CR63">63</xref></sup>.</p><p id="Par28">Biodistribution is particularly pertinent as clinical programs extended beyond hematological malignancies. With very few exceptions, CAR-T therapy has been ineffective in solid tumors. While reasons for this lackluster efficacy are multi-fold and uncertain, inefficient trafficking to the tumor microenvironment appears to be a primary cause<sup><xref ref-type="bibr" rid="CR64">64</xref></sup>. CAR-T expansion is typically orders of magnitude lower in solid tumor indications, likely a consequence of insufficient antigen exposure and CAR-stimulation. While many cell engineering approaches are underway to enhance solid tumor penetration<sup><xref ref-type="bibr" rid="CR65">65</xref></sup>, routine quantification of T cell migratory patterns in vivo would be an important step towards doing so systematically, and eventually informing predictive PBPK-type distribution models.</p></sec><sec id="Sec12"><title>Lymphodepletion response and resource competition between adoptive and patient T cells</title><p id="Par29">Chemotherapy-based lymphodepletion is required to pre-condition patients, or in other words, &#8216;make space&#8217; for exogenous T cells prior to CAR-T administration. This is typically achieved via a cyclophosphamide (Cy) and fludarabine (Flu) regimen initiated a week prior to CAR-T infusion<sup><xref ref-type="bibr" rid="CR66">66</xref></sup>. The physiological mechanisms which control circulating T cell counts are not fully understood, but cytokine availability is likely a key contributor. For example, the systemic concentration of the cytokine IL7 spikes in response to lymphodepletion<sup><xref ref-type="bibr" rid="CR67">67</xref></sup>, presumably because the &#8216;sink&#8217; is removed (circulating lymphocytes). If such homeostatic cytokines are produced at a continuous rate, this would set a maximal carrying capacity. Adoptive T cells would thereby compete for limited resources with patient (host) T cells as the immune system regenerates.</p><p id="Par30">Clinical trials have shown that the magnitude of lymphodepletion affects the <italic toggle="yes">Cmax</italic> of administered CARTs. More intensive chemotherapy, either via drug combinations (Cy vs. Flu/Cy)<sup><xref ref-type="bibr" rid="CR68">68</xref></sup> or dosing (30 vs. 60&#8201;mg/kg Cy)<sup><xref ref-type="bibr" rid="CR67">67</xref></sup> enhances the <italic toggle="yes">Cmax</italic> for CD19-CAR-T therapy by approximately an order of magnitude, improving progression-free survival. This phenomenon, endogenous T cells reconstituting alongside the administered CAR-Ts limit growth via competition for resources, can be explored mathematically by the inclusion of host T cells into our mechanistic PKPD model<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>. The depth of lymphodepletion enhances CAR-T exposure by freeing up cytokines and thereby enhancing the proliferation rate of the administered T cells (Fig. <xref rid="Fig5" ref-type="fig">5A</xref>). Similarly, the rate at which host T cells reconstitute relative to the administered CAR-T also affects exposure (Fig. <xref rid="Fig5" ref-type="fig">5B</xref>). This competitive growth phenomenon has been explored more rigorously using data from the ZUMA-1 trial of Yescarta in diffuse large B cell lymphoma<sup><xref ref-type="bibr" rid="CR69">69</xref></sup>. The authors reach similar conclusions, i.e., competition between exogenous vs. endogenous T cells limits CAR-T expansion, and the variable response to lymphodepletion between patients contributes to variance in CAR-T exposure and patient outcomes.<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><title>Effects of lympho-depletion and endogenous T cell reconstitution on CAR-T pharmacokinetics.</title><p><bold>A</bold> Circulating T cell counts and CAR-T pharmacokinetics following lympho-depletion with varying levels of intensity and fixed reconstitution kinetics. <bold>B</bold> Circulating T cell counts and CAR-T pharmacokinetics following lympho-depletion with a fixed level of intensity with varying T cell reconstitution kinetics.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1212" position="float" orientation="portrait" xlink:href="41540_2024_355_Fig5_HTML.jpg"/></fig></p><p id="Par31">What does this mean for clinical practice and drug development? The chemotherapy regimens used in current practice were developed empirically, out of experience with hematopoietic stem cell transplantation, rather than from model-optimized design. We imagine there is space for improvement based on &#8216;standard&#8217; PKPD modelling of Cy/Flu regimens<sup><xref ref-type="bibr" rid="CR70">70</xref></sup>. Newer, targeted lymphodepletion regimens are in development, and have proven beneficial in enhancing activity of CAR-T therapies (e.g., anti-CD52 alemtuzumab<sup><xref ref-type="bibr" rid="CR71">71</xref></sup>). These could likely be further optimized using PKPD modeling approaches. A first step would be routine monitoring and reporting of patient peripheral blood T cell counts alongside CAR-T kinetics. Finally, if cytokine availability limits CAR-T expansion, the cognate signals could be engineered into next-generation products. Indeed, constitutive IL15 receptor signaling constructs have proven effective in improving expansion and activity in pre-clinical studies<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>, essentially a mimetic of lymphodepletion.</p></sec><sec id="Sec13"><title>Allogeneic elimination of administered cells by patient immune systems</title><p id="Par32">All approved CAR-T products, and the majority in development, utilize autologous T cells as starting material. Patient-specific cell manufacturing poses a series of limitations: manufacturing logistics are quite complex, extended &#8216;vein-to-vein&#8217; wait times negatively affect patient outcomes<sup><xref ref-type="bibr" rid="CR72">72</xref></sup>, the complexity of multi-gene engineering is limited, and variability in starting material leads to products of inconsistent quality. The use of consistent, allogeneic T cells as starting material would potentially alleviate these constraints<sup><xref ref-type="bibr" rid="CR73">73</xref></sup>. However, the main barrier to allogeneic cell therapy is immune cross-reactivity. Administered T cells have the potential to recognize patient antigens and cause life-threatening graft-versus-host disease. Conversely, administered T cells will be recognized as foreign via major histocompatibility complex (MHC) mismatches by a patient&#8217;s reconstituting immune system. Thus, in addition to &#8216;competition for resources&#8217; between exogenous and endogenous T cells, allogeneic CAR-Ts will be subject to additional clearance as a patient&#8217;s immunity regenerates. Even for autologous CAR-Ts, there is evidence that humoral and cellular immunity directed against CAR-constructs limits exposure and activity to varying extents<sup><xref ref-type="bibr" rid="CR74">74</xref></sup>.</p><p id="Par33">The first clinical data reported on donor-derived, allogenic CAR-T therapy was the CALM trial of UCART19 for the treatment of refractory B cell acute lymphoblastic lymphoma (B-ALL). This is a CD19-targeted CAR-T bearing a <italic toggle="yes">TRAC</italic>-knockout, thereby removing donor TCR expression and potential for graft-vs-host disease. The anti-CD52 antibody alemtuzumab was used in addition standard Cy/Flu chemotherapy for enhanced lympho-depletion, but no MHC-gene editing strategies were employed<sup><xref ref-type="bibr" rid="CR75">75</xref></sup>. The product was eliminated on average much faster than the autologous-counterpart Kymriah, with elimination mirroring patient T cell reconstitution (Fig. <xref rid="Fig6" ref-type="fig">6A</xref>, B). Moreover, patients could be separated into groups (&#8216;persisters&#8217; and &#8216;non-persisters&#8217;) based on the rate of elimination, a difference explainable solely by differences in allogeneicity (Fig. <xref rid="Fig6" ref-type="fig">6C</xref>). Alemtuzumab exposure was identified as a predictor of response status<sup><xref ref-type="bibr" rid="CR71">71</xref></sup>, and a detailed mechanism-based model trained on the data concluded that allogeneic elimination is both the main driver of variance and barrier to durable efficacy<sup><xref ref-type="bibr" rid="CR76">76</xref></sup>.<fig id="Fig6" position="float" orientation="portrait"><label>Fig. 6</label><caption><title>Effects of allogeneic elimination and exemplary clinical data.</title><p><bold>A</bold> Reported individual patient pharmacokinetics (<italic toggle="yes">n</italic>&#8201;=&#8201;26) of the allogeneic product UCART19, separated categorically into &#8216;persisters&#8217; (P) and &#8216;non-persisters&#8217; (NP)<sup><xref ref-type="bibr" rid="CR76">76</xref></sup>. Raw data overlaid with a modified Kymriah-PKPD model<sup><xref ref-type="bibr" rid="CR45">45</xref></sup> incorporating allogeneic clearance, tuned to approximately match the population medians for the two patient categories. <bold>B</bold> Host T cell regeneration kinetics following lymphodepletion and UCART19 administration from the same patient cohort. <bold>C</bold> Simulated CAR-T pharmacokinetics over a 5-order of magnitude range of allogeneic elimination rates. <bold>D</bold> Reported individual patient pharmacokinetics (<italic toggle="yes">n</italic>&#8201;=&#8201;1) of the iPSC-derived product FT819, first (cycle 1, 90&#8201;M cells) and second dose (cycle 2, 180&#8201;M cells)<sup><xref ref-type="bibr" rid="CR100">100</xref></sup>, overlaid with population-pharmacokinetic simulations of Kymriah<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. <bold>E</bold> Exposure (60-day AUC) calculated for Kymriah, UCART19 and FT819, and simulated for the allogeneic PKPD model tuned to persister (red square) and non-persister (blue square) data. Boxes represent median &#177; 25 percentiles, and whiskers the min/max or 1.5-times the inter-quartile range from the box outline. <bold>F</bold> UCART19 and FT819 median exposures mapped onto a simulation-based Kymriah exposure-response model in CLL<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1320" position="float" orientation="portrait" xlink:href="41540_2024_355_Fig6_HTML.jpg"/></fig></p><p id="Par34">The use of donor-derived T cells as starting material still poses logistic challenges &#8211; notably finding a consistent, rigorously quality controlled source of donor cells for manufacturing. Induced pluripotent stem cells (iPSCs) offer a solution as a potentially limitless source of clonally derived, consistent starting material that could be produced in large batches. Progress has been made in differentiation protocols for generating functionally mature CD8+ T cells from iPSCs<sup><xref ref-type="bibr" rid="CR77">77</xref>&#8211;<xref ref-type="bibr" rid="CR79">79</xref></sup>, and technologies enabling GMP-compatible, scalable batch production are emerging<sup><xref ref-type="bibr" rid="CR80">80</xref>,<xref ref-type="bibr" rid="CR81">81</xref></sup>. The first clinical data on an iPSC-derived CAR-T product was reported by Fate Therapeutics on FT819, a CD19-targeted CAR-T bearing a <italic toggle="yes">TRAC</italic>-knockout<sup><xref ref-type="bibr" rid="CR82">82</xref></sup>. Efficacy reported in the first data readout was suboptimal, and the single patient PK data showed much faster clearance than autologous or donor-derived CAR-Ts (Fig. <xref rid="Fig6" ref-type="fig">6D</xref>). It is not possible to determine from this alone whether the lack of persistence is due to cell-intrinsic deficits, or enhanced elimination by patient immune recognition of the foreign cells. Regardless, mapping computed exposures (60-day AUC; Fig. <xref rid="Fig6" ref-type="fig">6E</xref>) to an exposure-response model built on Kymriah in CLL reveals that clearance fully accounts for the deficit in clinical activity (Fig. <xref rid="Fig6" ref-type="fig">6F</xref>). A primary challenge for the next generation of iPSC-CAR-T development is thus to first identify the mechanisms responsible for shortened persistence and then implement cell engineering strategies to overcome these deficits. This is a tall order, most likely requiring a combination of improved differentiation protocols, engineered signaling constructs which enhance memory cell generation<sup><xref ref-type="bibr" rid="CR83">83</xref></sup> plus MHC-editing strategies for immune-evasion<sup><xref ref-type="bibr" rid="CR84">84</xref></sup>.</p><p id="Par35">So far, we have shown the utility of mathematical models in characterizing the clinical pharmacology of engineered T cells. Specifically, we have highlighted the drug development challenges unique to this field, including product heterogeneity, tissue trafficking and biodistribution, lymphodepletion response and allogeneic elimination. These factors can significantly impact pharmacokinetics and efficacy, and model simulations may be employed to inform clinical development strategies. A grand challenge over the coming years will be to integrate clinical insights with advanced research technologies, and to rationally design next-generation products with improved therapeutic profiles. We believe biology-based, quantitative systems pharmacology models will be pivotal in addressing this challenge.</p></sec></sec><sec id="Sec14"><title>Translational modelling and next-generation T cell therapies</title><p id="Par36">Mathematical models are essential for product development and in silico prototyping in many industries. While human physiology is too complex and uncharted to fully recapitulate in a computer simulation, model-informed drug development (MIDD) still plays a vital role in decision-making across biopharma<sup><xref ref-type="bibr" rid="CR85">85</xref>,<xref ref-type="bibr" rid="CR86">86</xref></sup>. The models employed can be aligned on a spectrum from empirical to mechanistic. Empirical models (based purely on data and statistics, encompassing machine-learning to classic exposure-response equations) are useful for quantifying system behavior, identifying important variables, and specifying input-output relationships. However, they are constrained to interpolation within the bounds of the training data. As such, we cannot simulate the effect of dose schedule, tumor burden, T cell composition, lymphodepletion response, etc. if such variables were not included in model training. By incorporating established knowledge and biological hypotheses, mechanism-based models have the advantage of exploring &#8216;what if&#8217; scenarios in silico<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>.</p><p id="Par37">The sparse implementation of mathematical modelling in the cell therapy space can be attributed to limited data availability. While hundreds of CAR-T clinical trials have been conducted, the patient-level data for the vast majority remains locked. Population-averaged data, when published, is useful but obscures individual variability essential to deepening our understanding of this therapeutic class. Numerous legal, intellectual property and business factors play a role in the decision to withhold clinical data from public release. As an alternative, mathematical models are an efficient means of both encoding clinical results and sharing insights. Stein et al.<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>, for example, did not release the underlying clinical data for Kymriah, but the published mathematical model serves as a computational representation, amenable to subsequent reuse, modification, and benchmarking (as we have demonstrated). More broadly, executable computer code is a more consistent, formalized platform for sharing scientific findings than text and summary figures<sup><xref ref-type="bibr" rid="CR87">87</xref></sup>.</p><p id="Par38">Another primary challenge in model-informed development of T-cell therapies is the inadequacy of pre-clinical models. Therapeutic development relies upon the use of rapid and high-throughput in vitro and in vivo surrogates of clinical activity<sup><xref ref-type="bibr" rid="CR88">88</xref></sup>. For therapeutic T cells, the gold standard in vitro functional surrogate is the serial killing assay (repeated target cell lysis)<sup><xref ref-type="bibr" rid="CR89">89</xref></sup>. While it is routinely stated that pre-clinical models are &#8216;not predictive&#8217;, there exists, to our knowledge, no systematic studies qualifying this statement. We were unable to identify studies comparing in vitro or in vivo pre-clinical functional readouts to clinical data for CAR-T therapies. Moreover, the raw data readouts from such assays (cell counts) are highly dependent upon specifics of the assay design (i.e. time, Effector:Target ratio, cytokine supplements, etc.), which likely contributes to this pessimism. However, model parameters such as kinetic rate constants inferred from such data are more invariant to specifics of experimental design<sup><xref ref-type="bibr" rid="CR90">90</xref></sup> and thus facilitate clinical predictions.</p><p id="Par39">Simulations of a modified version of the &#8216;CARRGO&#8217; model<sup><xref ref-type="bibr" rid="CR91">91</xref></sup> (itself a derivative of the classic &#8220;predator-prey&#8221; model) reveal that the shape of tumor dynamic curves from serial re-stimulation assays can be quite complex, and interpretation non-intuitive (Fig. <xref rid="Fig7" ref-type="fig">7</xref>). However, fundamental features of T cell function (proliferation rate, cytotoxic activity, and exhaustion) yield distinct features that can be inferred using careful experimental design coupled with mathematical analyses. The effect of gene edits or other cell engineering strategies on such kinetic rates could be mapped onto PKPD models for clinical predictions. One such multi-scale translational model was developed to understand the dose-response properties of the BCMA-targeted CAR-T Abecma (bb2121), connecting in vitro, in vivo and clinical data<sup><xref ref-type="bibr" rid="CR92">92</xref></sup>. Though not used (to our knowledge) for prospective product design or lead selection, this model proves the technical feasibility of doing so.<fig id="Fig7" position="float" orientation="portrait"><label>Fig. 7</label><caption><title>Quantification of in vitro functional assays for translational systems pharmacology modelling.</title><p><bold>A</bold> CAR-T cell proliferation and tumor cell dynamics measured in in vitro and in vivo functional assays functional data can yield insights into fundamental biology and facilitate clinical predictions when quantified with systems pharmacology models (Created with BioRender.com). Model simulations of CAR-T cell and tumor cell interactions in a 24-hour serial restimulation assay reveal the complex, non-linear effects of drug product characteristics such as CAR-T cytotoxicity (<bold>B</bold>), proliferation (<bold>C</bold>), or exhaustion (<bold>D</bold>) on tumor cell survival.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1435" position="float" orientation="portrait" xlink:href="41540_2024_355_Fig7_HTML.jpg"/></fig></p><p id="Par40">A critical yet unresolved issue in the T cell therapy space is the fact that what makes an optimal phenotype for adoptive therapy remains elusive. Without robust critical quality attributes (CQAs) linking molecular features to function, it is not possible to rationally specify design or release criteria. The potential design space is so large (CAR/TCR designs, gene edits, synthetic biology-based regulatory switches, cell sources and expansion protocols) and the mechanisms linking molecular perturbations to function so complex and non-linear, classic one-at-a-time hypothesis testing is not a practically feasible approach to map the design space. High-throughput CRISPR-library-based screens coupled with single-cell transcriptome-based phenotyping and functional assays could however be utilized. These have proven effective in the design of novel CAR signaling constructs<sup><xref ref-type="bibr" rid="CR93">93</xref>,<xref ref-type="bibr" rid="CR94">94</xref></sup> and the identification of functional gene knock-ins<sup><xref ref-type="bibr" rid="CR95">95</xref></sup>. Coupling these datasets with biologically-informed mathematical models (i.e., signaling and transcriptional regulatory networks<sup><xref ref-type="bibr" rid="CR96">96</xref>,<xref ref-type="bibr" rid="CR97">97</xref></sup>) could be instrumental in both specifying CQAs, and predictively linking these attributes to cell culture inputs, a step towards Quality By Design for cell therapy manufacturing<sup><xref ref-type="bibr" rid="CR98">98</xref></sup>.</p><p id="Par41">Cell-based therapies are inherently more complex than other treatment modalities. A common refrain is &#8220;it&#8217;s too complicated to model&#8221; and the requisite simplifying assumptions ignore the nuances of biology. Instead, we see this as a strength. Model development (the careful specification of important variables along with the hypothetical or known mechanisms connecting them) and model calibration (the degree of certainty in the model and consistency with data) are valuable pressure tests. The resulting mathematical models are then quantitative representations of our mental constructs, and simulations are simply the consequences of our assumptions and assertations.</p><p id="Par42">There is flurry of research and development work in the T cell therapy space. Akin to Plato&#8217;s Allegory of the Cave<sup><xref ref-type="bibr" rid="CR99">99</xref></sup>, clinical observations and experimental data represent but flickering shadows cast from a deeper and more complex reality. Mathematical models enable one to synthesize those potential realities, test which are most consistent with the &#8220;flickering shadows&#8221; and explore the consequences of such inferences. If we are to translate the plethora of novel cell designs and manufacturing protocols into the next generation of clinical products, mathematical models will be essential to interpret the shadows, and assemble our perceptions into coherent theory.</p></sec></sec><sec id="Sec15"><title>Methods</title><sec id="Sec16"><title>PKPD model simulations</title><p id="Par43">A standard two-compartment pharmacokinetic model with linear absorption was simulated for illustrative purposes. Efficacy and toxicity were linked via direct response to serum concentration via Hill equations, and simulations executed over a dose range of 2 through 18 (arbitrary units). Equations were coded in MATLAB&#8217;s SimBiology toolbox, and all simulations were executed using MATLAB R2022b.</p></sec><sec id="Sec17"><title>Empirical CAR-T pharmacokinetic model simulations</title><p id="Par44">Model equations and baseline parameters describing population pharmacokinetics of Kymriah in B-ALL were taken from Stein et al.<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. Responder vs. Non-responder simulations were executed by encoding differences in Cmax/fold expansion as reported by Liu et al.<sup><xref ref-type="bibr" rid="CR35">35</xref></sup> for the same clinical study (R vs. NR Cmax equivalent to 10<sup>5</sup> vs. 10<sup>3</sup> counts/<underline>&#181;</underline>g DNA), and statistics calculated from 1000 simulations (virtual patients). Dose response simulations were executed by scanning initial CAR-T amounts (<italic toggle="yes">C</italic><sub><italic toggle="yes">0</italic></sub>) across a 50-fold scaled range with a median dose of 10<sup>8</sup> cells representing a dose ranging study of 10<sup>7</sup> to 5&#8201;&#215;&#8201;10<sup>8</sup> cells, approximately equivalent to that reported in the original BLA<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>. Grid simulations of CAR-T cell expansion effect size vs. population variance were executed by simulating the model (<italic toggle="yes">n</italic>&#8201;=&#8201;10,000 virtual patients) with the maximum cell expansion &#8216;Cmax&#8217; parameter scaled from 1- to 10-fold the reported mean value (24000 copies/<underline>&#181;</underline>g), and the log-variance (&#8216;OMEGA&#8217;) scaled from 1 to 0.1-fold the reported range across all six model parameters. AUC<sub>28d</sub> was calculated based on a daily sampling schedule, and minimum sample sizes were estimated at each point in the grid by comparison to the control AUC<sub>28</sub> using a two-sided t-test with a power of 80% and significance of 0.05, using MATLAB&#8217;s <italic toggle="yes">sampsizepwr</italic> function.</p><p id="Par45">Translation between counts/<underline>&#181;</underline>g DNA to cells/<underline>&#181;</underline>L was estimated using CD19-CAR-T data reported by Kallos et al.<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>: we estimate 1 count/<underline>&#181;</underline>g DNA&#8201;&#8776;&#8201;0.05 cells/&#181;L.</p></sec><sec id="Sec18"><title>Mechanistic CAR-T pharmacokinetic simulations</title><p id="Par46">To simulate the effect of memory cell proliferation rate on CAR-T pharmacokinetics, the mechanism-based CAR-T PKPD model published by Kirouac et al.<sup><xref ref-type="bibr" rid="CR45">45</xref></sup> was executed with the <italic toggle="yes">&#181;</italic><sub><italic toggle="yes">M</italic></sub> parameter varied from 0.1 to 2-times the reported estimate, using a single parameter vector (CR patient #1).</p><p id="Par47">To simulate the effect of T cell distribution into tissues, the published model structure was edited in SimBiology model builder. A second &#8216;tissue&#8217; compartment was created, witch two parameters quantifying T cell distributing from blood to tissue (rate <italic toggle="yes">k</italic><sub><italic toggle="yes">12</italic></sub>) and tissue to blood (rate <italic toggle="yes">k</italic><sub><italic toggle="yes">21</italic></sub>) based on mass action kinetics. The k<sub>21</sub> parameter was multiplied by an autonomous (time-dependent) term to simulate a time delay (<italic toggle="yes">TD</italic>) post-infusion as:<disp-formula id="Equ1"><label>1</label><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${TD}={{time}}^{k}/\left({{{TD}}_{50}}^{k}+{{time}}^{k}\right),$$\end{document}</tex-math><mml:math id="M2"><mml:mrow><mml:mi mathvariant="italic">TD</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="italic">time</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mo>/</mml:mo><mml:mrow><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:msup><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="italic">TD</mml:mi></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mi mathvariant="italic">time</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="41540_2024_355_Article_Equ1.gif"/></alternatives></disp-formula>with <italic toggle="yes">TD</italic><sub><italic toggle="yes">50</italic></sub>&#8201;=&#8201;12 days and <italic toggle="yes">k</italic>&#8201;=&#8201;4 for switch-type behavior. With <italic toggle="yes">k</italic><sub><italic toggle="yes">12</italic></sub> (tissue distribution) fixed at 6 day<sup>&#8722;1</sup>, simulations were executed with the blood re-distribution rate (<italic toggle="yes">k</italic><sub><italic toggle="yes">21</italic></sub>) varied over 4 orders of magnitude.</p><p id="Par48">To simulate the effect of lymphodepletion and exogenous vs. endogenous T cell competition, host T cell (<italic toggle="yes">Th</italic>) reconstitution was described using a saturating growth rate ordinary differential equation:<disp-formula id="Equ2"><label>2</label><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\frac{{dTh}}{{dt}}={\mu }_{h}\bullet {T}_{K}/\left({T}_{K}+{T}_{t}\right)\cdot {T}_{h},$$\end{document}</tex-math><mml:math id="M4"><mml:mrow><mml:mfrac><mml:mrow><mml:mi mathvariant="italic">dTh</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">dt</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>&#956;</mml:mi></mml:mrow><mml:mrow><mml:mi>h</mml:mi></mml:mrow></mml:msub><mml:mo>&#8729;</mml:mo><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>K</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>/</mml:mo><mml:mrow><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>K</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow><mml:mo>&#8901;</mml:mo><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>h</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="41540_2024_355_Article_Equ2.gif"/></alternatives></disp-formula>were <italic toggle="yes">T</italic><sub><italic toggle="yes">t</italic></sub>&#8201;=&#8201;<italic toggle="yes">Th</italic>&#8201;+&#8201;<italic toggle="yes">T</italic><sub><italic toggle="yes">CART</italic></sub> (total circulating T cells), <inline-formula id="IEq1"><alternatives><tex-math id="M5">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\mu }_{h}$$\end{document}</tex-math><mml:math id="M6"><mml:msub><mml:mrow><mml:mi>&#956;</mml:mi></mml:mrow><mml:mrow><mml:mi>h</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41540_2024_355_Article_IEq1.gif"/></alternatives></inline-formula> is the growth rate of host T cells and <italic toggle="yes">T</italic><sub><italic toggle="yes">K</italic></sub> the carrying capacity, set at 50 cell/&#181;L such that steady state circulating T cell counts saturate at approximately 10<sup>3</sup> cell/&#181;L. The CAR-T proliferation rates were all multiplied by the saturation function (<inline-formula id="IEq2"><alternatives><tex-math id="M7">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${T}_{K}/\left({T}_{K}+{T}_{t}\right)$$\end{document}</tex-math><mml:math id="M8"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>K</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>/</mml:mo><mml:mrow><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>K</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41540_2024_355_Article_IEq2.gif"/></alternatives></inline-formula>) such that proliferation is equivalently limited by total circulating T cell counts.</p><p id="Par49">Simulations were executed by varying the initial number of host T cells post-lymphodepletion over 3-orders of magnitude (from 0.05 to 500 cells/&#181;L) while keeping the host T cell growth rate fixed at 0.35 day<sup>&#8722;1</sup>, or fixing the post-lymphodepletion T cell count at 0.5 cell/&#181;L while varying the growth rate over 2-orders of magnitude from 0.03 to 3 day<sup>&#8722;1</sup>.</p><p id="Par50">To simulate the effect of allogeneic clearance, each equation in the above model was edited to include an additional term modelling direct host T cell CAR-T killing via mass-action kinetics:<disp-formula id="Equ3"><label>3</label><alternatives><tex-math id="M9">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\frac{d{T}_{{CART}}}{{dt}}=\ldots -{k}_{{kill}}\bullet {T}_{{CART}}\bullet {T}_{h}.$$\end{document}</tex-math><mml:math id="M10"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">CART</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="italic">dt</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mo>&#8230;</mml:mo><mml:mo>&#8722;</mml:mo><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">kill</mml:mi></mml:mrow></mml:msub><mml:mo>&#8729;</mml:mo><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">CART</mml:mi></mml:mrow></mml:msub><mml:mo>&#8729;</mml:mo><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>h</mml:mi></mml:mrow></mml:msub><mml:mo>.</mml:mo></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="41540_2024_355_Article_Equ3.gif"/></alternatives></disp-formula></p><p id="Par51">Simulations were executed by fixing the initial host T cell count (<italic toggle="yes">T</italic><sub><italic toggle="yes">h</italic></sub>) post-lympho-depletion at 0.5 cell/&#181;L and growth rate (<inline-formula id="IEq3"><alternatives><tex-math id="M11">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\mu }_{h}$$\end{document}</tex-math><mml:math id="M12"><mml:msub><mml:mrow><mml:mi>&#956;</mml:mi></mml:mrow><mml:mrow><mml:mi>h</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41540_2024_355_Article_IEq3.gif"/></alternatives></inline-formula>) at 0.35 day<sup>&#8722;1</sup> and varying the allogeneic cell killing rate (<italic toggle="yes">k</italic><sub><italic toggle="yes">kill</italic></sub>) from 10<sup>&#8722;12</sup> to 10<sup>&#8722;7</sup> cell<sup>&#8722;1</sup>day<sup>&#8722;1</sup>. Persisters vs. non-persisters were simulated by setting the allogeneic cell killing rate (<italic toggle="yes">k</italic><sub><italic toggle="yes">kill</italic></sub>) at 0 and 7 &#215; 10<sup>&#8722;9</sup> cell<sup>&#8722;1</sup>day<sup>&#8722;1</sup>, respectively.</p></sec><sec id="Sec19"><title>UCART19 and FT819 data</title><p id="Par52">CAR-T pharmacokinetic data was digitized using Graph Grabber v2 (Quintessa). For UCART19, individual patient data was extracted from the supplemental figures in Derippe et al.<sup><xref ref-type="bibr" rid="CR76">76</xref></sup>, and FT819 using a figure from an ASH 2022 poster on interim FT-819-101 trial data<sup><xref ref-type="bibr" rid="CR100">100</xref></sup>.</p></sec><sec id="Sec20"><title>Simulations of serial restimulation assays</title><p id="Par53">We adapted the CARRGO predator-prey model of CAR-T cell (<italic toggle="yes">E</italic>) and tumor (<italic toggle="yes">T</italic>) cell interactions<sup><xref ref-type="bibr" rid="CR91">91</xref></sup> to include CAR-T cell exhaustion upon interaction with Tumor cells (rate constant <inline-formula id="IEq4"><alternatives><tex-math id="M13">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\nu$$\end{document}</tex-math><mml:math id="M14"><mml:mi>&#957;</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41540_2024_355_Article_IEq4.gif"/></alternatives></inline-formula>):<disp-formula id="Equ4"><label>4</label><alternatives><tex-math id="M15">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\frac{{dE}}{{dt}}=\gamma E-\theta E-\nu {ET},$$\end{document}</tex-math><mml:math id="M16"><mml:mrow><mml:mfrac><mml:mrow><mml:mi mathvariant="italic">dE</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">dt</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mi>&#947;</mml:mi><mml:mi>E</mml:mi><mml:mo>&#8722;</mml:mo><mml:mi>&#952;</mml:mi><mml:mi>E</mml:mi><mml:mo>&#8722;</mml:mo><mml:mi>&#957;</mml:mi><mml:mi mathvariant="italic">ET</mml:mi><mml:mo>,</mml:mo></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="41540_2024_355_Article_Equ4.gif"/></alternatives></disp-formula><disp-formula id="Equ5"><label>5</label><alternatives><tex-math id="M17">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\frac{{dT}}{{dt}}=\rho T\left(1-\beta T\right)-\kappa {ET},$$\end{document}</tex-math><mml:math id="M18"><mml:mrow><mml:mfrac><mml:mrow><mml:mi mathvariant="italic">dT</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">dt</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mi>&#961;</mml:mi><mml:mi>T</mml:mi><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#8722;</mml:mo><mml:mi>&#946;</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mo>&#8722;</mml:mo><mml:mi>&#954;</mml:mi><mml:mi mathvariant="italic">ET</mml:mi><mml:mo>,</mml:mo></mml:mrow></mml:math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="41540_2024_355_Article_Equ5.gif"/></alternatives></disp-formula>and simulated 3, 24-hour restimulations at 1:1 E:T where 5000 tumor cells were added at the end of each stimulation. Baseline model parameters were <inline-formula id="IEq5"><alternatives><tex-math id="M19">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\rho =\gamma =\log (2)/24$$\end{document}</tex-math><mml:math id="M20"><mml:mrow><mml:mi>&#961;</mml:mi><mml:mo>=</mml:mo><mml:mi>&#947;</mml:mi><mml:mo>=</mml:mo><mml:mi>log</mml:mi><mml:mo>(</mml:mo><mml:mn>2</mml:mn><mml:mo>)</mml:mo><mml:mo>/</mml:mo><mml:mn>24</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41540_2024_355_Article_IEq5.gif"/></alternatives></inline-formula> hour<sup>&#8722;1</sup>, <inline-formula id="IEq6"><alternatives><tex-math id="M21">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\beta ={10}^{-5}$$\end{document}</tex-math><mml:math id="M22"><mml:mrow><mml:mi>&#946;</mml:mi><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>&#8722;</mml:mo><mml:mn>5</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41540_2024_355_Article_IEq6.gif"/></alternatives></inline-formula> cell<sup>&#8722;1</sup>, <inline-formula id="IEq7"><alternatives><tex-math id="M23">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\kappa ={10}^{-5}$$\end{document}</tex-math><mml:math id="M24"><mml:mrow><mml:mi>&#954;</mml:mi><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>&#8722;</mml:mo><mml:mn>5</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41540_2024_355_Article_IEq7.gif"/></alternatives></inline-formula> hour<sup>&#8722;1</sup> cell<sup>&#8722;1</sup>, <inline-formula id="IEq8"><alternatives><tex-math id="M25">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\theta ={10}^{-3}$$\end{document}</tex-math><mml:math id="M26"><mml:mrow><mml:mi>&#952;</mml:mi><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>&#8722;</mml:mo><mml:mn>3</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41540_2024_355_Article_IEq8.gif"/></alternatives></inline-formula> hour<sup>&#8722;1</sup>, and <inline-formula id="IEq9"><alternatives><tex-math id="M27">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\nu ={10}^{-6}$$\end{document}</tex-math><mml:math id="M28"><mml:mrow><mml:mi>&#957;</mml:mi><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>&#8722;</mml:mo><mml:mn>6</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41540_2024_355_Article_IEq9.gif"/></alternatives></inline-formula>, with <inline-formula id="IEq10"><alternatives><tex-math id="M29">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$E\left(0\right)=T\left(0\right)=5000$$\end{document}</tex-math><mml:math id="M30"><mml:mrow><mml:mi>E</mml:mi><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:mfenced></mml:mrow><mml:mo>=</mml:mo><mml:mi>T</mml:mi><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:mfenced></mml:mrow><mml:mo>=</mml:mo><mml:mn>5000</mml:mn></mml:mrow></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41540_2024_355_Article_IEq10.gif"/></alternatives></inline-formula> cells. We simulated the model over a range of parameter sweeps by fold-changing each model parameter multiplicatively one-at-a-time with the following fold changes: 1/3, 1/2, 1, 2, 3 for cytotoxicity (<inline-formula id="IEq11"><alternatives><tex-math id="M31">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\kappa$$\end{document}</tex-math><mml:math id="M32"><mml:mi>&#954;</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41540_2024_355_Article_IEq11.gif"/></alternatives></inline-formula>) and proliferation (<inline-formula id="IEq12"><alternatives><tex-math id="M33">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\gamma$$\end{document}</tex-math><mml:math id="M34"><mml:mi>&#947;</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41540_2024_355_Article_IEq12.gif"/></alternatives></inline-formula>), and 1/2, 1, 3, 5, 7 for exhaustion (<inline-formula id="IEq13"><alternatives><tex-math id="M35">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\nu$$\end{document}</tex-math><mml:math id="M36"><mml:mi>&#957;</mml:mi></mml:math><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41540_2024_355_Article_IEq13.gif"/></alternatives></inline-formula>).</p></sec><sec id="Sec21"><title>Reporting summary</title><p id="Par54">Further information on research design is available in the <xref rid="MOESM1" ref-type="media">Nature Research Reporting Summary</xref> linked to this article.</p></sec></sec><sec sec-type="supplementary-material"><sec id="Sec22"><title>Supplementary information</title><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41540_2024_355_MOESM1_ESM.pdf" position="float" orientation="portrait"><caption><p>Reporting Summary</p></caption></media></supplementary-material>
</p></sec></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><sec><title>Supplementary information</title><p>The online version contains supplementary material available at 10.1038/s41540-024-00355-3.</p></sec><ack><title>Acknowledgements</title><p>This manuscript originated from a presentation given at the 2023 Federation of Clinical Immunology Societies (FOCIS) Cancer Immunity &amp; Immunotherapy course. We would like to thank Asha Pillai for spurring the concept and providing helpful feedback on content, as well as Avisek Deyati, Ismael Samudio, Irja Elliott Donaghue, Muluken Bellew, Amanda Rikard, Chris Bond and Peter Zandstra for ideas and feedback.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>D.C.K.: Initial conception and design. D.C.K. and C.Z.: Analysis and interpretation of data. D.C.K., C.Z. and D.M.: Drafting, revision of intellectual content and writing.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>All data and models were extracted from prior publications.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par55">The authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cappell</surname><given-names>KM</given-names></name><name name-style="western"><surname>Kochenderfer</surname><given-names>JN</given-names></name></person-group><article-title>Long-term outcomes following CAR T cell therapy: what we know so far</article-title><source>Nat. Rev. Clin. Oncol.</source><year>2023</year><volume>20</volume><fpage>359</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1038/s41571-023-00754-1</pub-id><pub-id pub-id-type="pmid">37055515</pub-id><pub-id pub-id-type="pmcid">PMC10100620</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>MacKay</surname><given-names>M</given-names></name><etal/></person-group><article-title>The therapeutic landscape for cells engineered with chimeric antigen receptors</article-title><source>Nat. Biotechnol.</source><year>2020</year><volume>38</volume><fpage>233</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1038/s41587-019-0329-2</pub-id><pub-id pub-id-type="pmid">31907405</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weber</surname><given-names>EW</given-names></name><name name-style="western"><surname>Maus</surname><given-names>MV</given-names></name><name name-style="western"><surname>Mackall</surname><given-names>CL</given-names></name></person-group><article-title>The emerging landscape of immune cell therapies</article-title><source>Cell</source><year>2020</year><volume>181</volume><fpage>46</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.03.001</pub-id><pub-id pub-id-type="pmid">32243795</pub-id><pub-id pub-id-type="pmcid">PMC8900215</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sheiner</surname><given-names>LB</given-names></name><name name-style="western"><surname>Steimer</surname><given-names>J-L</given-names></name></person-group><article-title>Pharmacokinetic/Pharmacodynamic modeling in drug development</article-title><source>Annu. Rev. Pharmacol. Toxicol.</source><year>2000</year><volume>40</volume><fpage>67</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1146/annurev.pharmtox.40.1.67</pub-id><pub-id pub-id-type="pmid">10836128</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>DK</given-names></name></person-group><article-title>Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics</article-title><source>J. Pharmacokinet. Pharmacodyn.</source><year>2015</year><volume>42</volume><fpage>553</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1007/s10928-015-9447-8</pub-id><pub-id pub-id-type="pmid">26373957</pub-id><pub-id pub-id-type="pmcid">PMC4593704</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grant</surname><given-names>J</given-names></name><name name-style="western"><surname>Hua</surname><given-names>F</given-names></name><name name-style="western"><surname>Apgar</surname><given-names>JF</given-names></name><name name-style="western"><surname>Burke</surname><given-names>JM</given-names></name><name name-style="western"><surname>Marcantonio</surname><given-names>DH</given-names></name></person-group><article-title>Mechanistic PK/PD modeling to address early-stage biotherapeutic dosing feasibility questions</article-title><source>mAbs</source><year>2023</year><volume>15</volume><fpage>2192251</fpage><pub-id pub-id-type="doi">10.1080/19420862.2023.2192251</pub-id><pub-id pub-id-type="pmid">36951503</pub-id><pub-id pub-id-type="pmcid">PMC10038042</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>H</given-names></name><name name-style="western"><surname>Rowland&#8208;Yeo</surname><given-names>K</given-names></name></person-group><article-title>Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development</article-title><source>CPT: Pharmacomet. Syst. Pharmacol.</source><year>2013</year><volume>2</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/psp.2013.41</pub-id><pub-id pub-id-type="pmcid">PMC3828005</pub-id><pub-id pub-id-type="pmid">23945604</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gadkar</surname><given-names>K</given-names></name><name name-style="western"><surname>Kirouac</surname><given-names>D</given-names></name><name name-style="western"><surname>Mager</surname><given-names>D</given-names></name><name name-style="western"><surname>van der Graaf</surname><given-names>PH</given-names></name><name name-style="western"><surname>Ramanujan</surname><given-names>S</given-names></name></person-group><article-title>A six&#8208;stage workflow for robust application of systems pharmacology</article-title><source>Cpt Pharmacomet. Syst. Pharm.</source><year>2016</year><volume>5</volume><fpage>235</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1002/psp4.12071</pub-id><pub-id pub-id-type="pmcid">PMC4879472</pub-id><pub-id pub-id-type="pmid">27299936</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marshall</surname><given-names>S</given-names></name><etal/></person-group><article-title>Model&#8208;Informed drug discovery and development: current industry good practice and regulatory expectations and future perspectives</article-title><source>CPT: Pharmacomet. Syst. Pharmacol.</source><year>2019</year><volume>8</volume><fpage>87</fpage><lpage>96</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/psp4.12372</pub-id><pub-id pub-id-type="pmcid">PMC6389350</pub-id><pub-id pub-id-type="pmid">30411538</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nukala</surname><given-names>U</given-names></name><name name-style="western"><surname>Messan</surname><given-names>MR</given-names></name><name name-style="western"><surname>Yogurtcu</surname><given-names>ON</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H</given-names></name></person-group><article-title>A systematic review of the efforts and hindrances of modeling and simulation of CAR T-cell Therapy</article-title><source>AAPS J.</source><year>2021</year><volume>23</volume><fpage>52</fpage><pub-id pub-id-type="doi">10.1208/s12248-021-00579-9</pub-id><pub-id pub-id-type="pmid">33835308</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mody</surname><given-names>H</given-names></name><etal/></person-group><article-title>Best Practices &amp; Considerations for Clinical Pharmacology &amp; Pharmacometric Aspects for Optimal Development of CAR-T &amp; TCR-T Cell Therapies: An Industry Perspective</article-title><source>Clin. Pharmacol. Ther.</source><year>2023</year><volume>11</volume><fpage>530</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1002/cpt.2986</pub-id><pub-id pub-id-type="pmid">37393588</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qi</surname><given-names>T</given-names></name><name name-style="western"><surname>McGrath</surname><given-names>K</given-names></name><name name-style="western"><surname>Ranganathan</surname><given-names>R</given-names></name><name name-style="western"><surname>Dotti</surname><given-names>G</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y</given-names></name></person-group><article-title>Cellular kinetics: A clinical and computational review of CAR-T cell pharmacology</article-title><source>Adv. Drug Deliv. Rev.</source><year>2022</year><volume>188</volume><fpage>114421</fpage><pub-id pub-id-type="doi">10.1016/j.addr.2022.114421</pub-id><pub-id pub-id-type="pmid">35809868</pub-id><pub-id pub-id-type="pmcid">PMC9520251</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laughlin</surname><given-names>AMM</given-names></name><name name-style="western"><surname>Milligan</surname><given-names>PA</given-names></name><name name-style="western"><surname>Yee</surname><given-names>C</given-names></name><name name-style="western"><surname>Bergstrand</surname><given-names>M</given-names></name></person-group><article-title>Model-informed drug development of autologous CAR-T cell therapy: Strategies to optimize CAR-T cell exposure leveraging cell kinetic/dynamic modeling</article-title><source>CPT: Pharmacomet. Syst. Pharmacol.</source><year>2023</year><volume>12</volume><fpage>1577</fpage><lpage>1590</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/psp4.13011</pub-id><pub-id pub-id-type="pmcid">PMC10681459</pub-id><pub-id pub-id-type="pmid">37448343</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaudhury</surname><given-names>A</given-names></name><etal/></person-group><article-title>Chimeric antigen receptor T cell therapies: a review of cellular kinetic&#8208;pharmacodynamic modeling approaches</article-title><source>J. Clin. Pharm.</source><year>2020</year><volume>60</volume><fpage>S147</fpage><lpage>S159</lpage><pub-id pub-id-type="doi">10.1002/jcph.1691</pub-id><pub-id pub-id-type="pmid">33205434</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalos</surname><given-names>M</given-names></name><etal/></person-group><article-title>T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia</article-title><source>Sci. Transl. Med.</source><year>2011</year><volume>3</volume><fpage>95ra73</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.3002842</pub-id><pub-id pub-id-type="pmid">21832238</pub-id><pub-id pub-id-type="pmcid">PMC3393096</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>D</given-names></name><etal/></person-group><article-title>Complex PK-PD of an engineered IL-15/IL-15R&#945;&#8211;Fc fusion protein in cynomolgus monkeys: QSP modeling of lymphocyte dynamics</article-title><source>Eur. J. Pharm. Sci.</source><year>2023</year><volume>186</volume><fpage>106450</fpage><pub-id pub-id-type="doi">10.1016/j.ejps.2023.106450</pub-id><pub-id pub-id-type="pmid">37084985</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferl</surname><given-names>GZ</given-names></name><etal/></person-group><article-title>A preclinical population pharmacokinetic model for Anti&#8208;CD20/CD3 T&#8208;cell&#8208;dependent bispecific antibodies</article-title><source>Clin. Transl. Sci.</source><year>2018</year><volume>11</volume><fpage>296</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1111/cts.12535</pub-id><pub-id pub-id-type="pmid">29351372</pub-id><pub-id pub-id-type="pmcid">PMC5944627</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McLane</surname><given-names>LM</given-names></name><name name-style="western"><surname>Abdel-Hakeem</surname><given-names>MS</given-names></name><name name-style="western"><surname>Wherry</surname><given-names>EJ</given-names></name></person-group><article-title>CD8 T. cell exhaustion during chronic viral infection and cancer</article-title><source>Annu Rev. Immunol.</source><year>2015</year><volume>37</volume><fpage>1</fpage><lpage>39</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-immunol-041015-055318</pub-id><pub-id pub-id-type="pmid">30676822</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melenhorst</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Decade-long leukaemia remissions with persistence of CD4+ CAR T cells</article-title><source>Nature</source><year>2022</year><volume>602</volume><fpage>503</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-04390-6</pub-id><pub-id pub-id-type="pmid">35110735</pub-id><pub-id pub-id-type="pmcid">PMC9166916</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>ND</given-names></name><etal/></person-group><article-title>Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia</article-title><source>Nat. Med.</source><year>2023</year><volume>29</volume><fpage>1700</fpage><lpage>1709</lpage><pub-id pub-id-type="doi">10.1038/s41591-023-02415-3</pub-id><pub-id pub-id-type="pmid">37407840</pub-id><pub-id pub-id-type="pmcid">PMC10353931</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stein</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Tisagenlecleucel model&#8208;based cellular kinetic analysis of chimeric antigen receptor&#8211;T cells</article-title><source>Cpt Pharmacomet. Syst. Pharm.</source><year>2019</year><volume>8</volume><fpage>285</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1002/psp4.12388</pub-id><pub-id pub-id-type="pmcid">PMC6539725</pub-id><pub-id pub-id-type="pmid">30848084</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">FDA Division of Clinical Evaluation and Pharmacology/Toxocilogy. Clinical Pharmacology BLA Review - KYMRIAH (tisagenlecleucel). <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/kymriah-tisagenlecleucel">www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/kymriah-tisagenlecleucel</ext-link> (2017).</mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">FA Division of Clinical Evaluation and Pharmacology/Toxicology. Clinical Pharmacology BLA Review - YESCARTA (axicabtagene ciloleucel). <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/kymriah-tisagenlecleucel">www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/yescarta-axicabtagene-ciloleucel</ext-link> (2017).</mixed-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hosseini</surname><given-names>I</given-names></name><etal/></person-group><article-title>Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling</article-title><source>Npj Syst. Biol. Appl</source><year>2020</year><volume>6</volume><fpage>28</fpage><pub-id pub-id-type="doi">10.1038/s41540-020-00145-7</pub-id><pub-id pub-id-type="pmid">32859946</pub-id><pub-id pub-id-type="pmcid">PMC7455723</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frigault</surname><given-names>M</given-names></name><etal/></person-group><article-title>Dose fractionation of CAR-T cells. A systematic review of clinical outcomes</article-title><source>J. Exp. Clin. Cancer Res.</source><year>2023</year><volume>42</volume><fpage>11</fpage><pub-id pub-id-type="doi">10.1186/s13046-022-02540-w</pub-id><pub-id pub-id-type="pmid">36627710</pub-id><pub-id pub-id-type="pmcid">PMC9830795</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davit</surname><given-names>BM</given-names></name><etal/></person-group><article-title>Implementation of a reference-scaled average bioequivalence approach for highly variable generic drug products by the US Food and Drug Administration</article-title><source>AAPS J.</source><year>2012</year><volume>14</volume><fpage>915</fpage><lpage>924</lpage><pub-id pub-id-type="doi">10.1208/s12248-012-9406-x</pub-id><pub-id pub-id-type="pmid">22972221</pub-id><pub-id pub-id-type="pmcid">PMC3475857</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>AP</given-names></name><etal/></person-group><article-title>Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model</article-title><source>MABS</source><year>2019</year><volume>12</volume><fpage>1688616</fpage><pub-id pub-id-type="doi">10.1080/19420862.2019.1688616</pub-id><pub-id pub-id-type="pmcid">PMC6927769</pub-id><pub-id pub-id-type="pmid">31852337</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mart&#237;nez-Rubio</surname><given-names>&#193;</given-names></name><etal/></person-group><article-title>A mathematical description of the bone marrow dynamics during CAR T-cell therapy in B-cell childhood acute lymphoblastic leukemia</article-title><source>Int J. Mol. Sci.</source><year>2021</year><volume>22</volume><fpage>6371</fpage><pub-id pub-id-type="doi">10.3390/ijms22126371</pub-id><pub-id pub-id-type="pmid">34198713</pub-id><pub-id pub-id-type="pmcid">PMC8232108</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turtle</surname><given-names>CJ</given-names></name><etal/></person-group><article-title>CD19 CAR&#8211;T cells of defined CD4+:CD8+ composition in adult B cell ALL patients</article-title><source>J. Clin. Invest</source><year>2016</year><volume>126</volume><fpage>2123</fpage><lpage>2138</lpage><pub-id pub-id-type="doi">10.1172/JCI85309</pub-id><pub-id pub-id-type="pmid">27111235</pub-id><pub-id pub-id-type="pmcid">PMC4887159</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zirkelbach</surname><given-names>JF</given-names></name><etal/></person-group><article-title>Improving dose-optimization processes used in oncology drug development to minimize toxicity and. maximize benefit patients</article-title><source>J. Clin. Oncol.</source><year>2022</year><volume>40</volume><fpage>3489</fpage><lpage>3500</lpage><pub-id pub-id-type="doi">10.1200/JCO.22.00371</pub-id><pub-id pub-id-type="pmid">36095296</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sommer</surname><given-names>C</given-names></name><etal/></person-group><article-title>Preclinical evaluation of allogeneic CAR T cells targeting BCMA for the treatment of multiple myeloma</article-title><source>Mol. Ther.</source><year>2019</year><volume>27</volume><fpage>1126</fpage><lpage>1138</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2019.04.001</pub-id><pub-id pub-id-type="pmid">31005597</pub-id><pub-id pub-id-type="pmcid">PMC6554542</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rotte</surname><given-names>A</given-names></name><etal/></person-group><article-title>Dose&#8211;response correlation for CAR-T cells: a systematic review of clinical studies</article-title><source>J. Immunother. Cancer</source><year>2022</year><volume>10</volume><fpage>e005678</fpage><pub-id pub-id-type="doi">10.1136/jitc-2022-005678</pub-id><pub-id pub-id-type="pmid">36549782</pub-id><pub-id pub-id-type="pmcid">PMC9791395</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="other">FDA Guidance or Industry. <italic toggle="yes">Studying Multiple Versions of a Cellular or Gene Therapy Product in an Early-Phase Clinical Trial: Guidance for Industry</italic>. FDA-2021-D-0776 (2022).</mixed-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moore</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Heyward</surname><given-names>J</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>G</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>GC</given-names></name></person-group><article-title>Variation in the estimated costs of pivotal clinical benefit trials supporting the US approval of new therapeutic agents, 2015&#8211;2017: a cross-sectional study</article-title><source>BMJ Open</source><year>2020</year><volume>10</volume><fpage>e038863</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2020-038863</pub-id><pub-id pub-id-type="pmid">32532786</pub-id><pub-id pub-id-type="pmcid">PMC7295430</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name><etal/></person-group><article-title>Model-based cellular kinetic analysis of chimeric antigen receptor-T cells in humans</article-title><source>Clin. Pharmacol. Ther.</source><year>2020</year><volume>109</volume><fpage>716</fpage><lpage>727</lpage><pub-id pub-id-type="doi">10.1002/cpt.2040</pub-id><pub-id pub-id-type="pmid">33002189</pub-id><pub-id pub-id-type="pmcid">PMC7959329</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bachireddy</surname><given-names>P</given-names></name><etal/></person-group><article-title>Mapping the evolution of T cell states during response and resistance to adoptive cellular therapy</article-title><source>Cell Rep.</source><year>2021</year><volume>37</volume><fpage>109992</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2021.109992</pub-id><pub-id pub-id-type="pmid">34758319</pub-id><pub-id pub-id-type="pmcid">PMC9035342</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Good</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy</article-title><source>Nat. Med.</source><year>2022</year><volume>28</volume><fpage>1860</fpage><lpage>1871</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-01960-7</pub-id><pub-id pub-id-type="pmid">36097223</pub-id><pub-id pub-id-type="pmcid">PMC10917089</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haradhvala</surname><given-names>NJ</given-names></name><etal/></person-group><article-title>Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma</article-title><source>Nat. Med.</source><year>2022</year><volume>28</volume><fpage>1848</fpage><lpage>1859</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-01959-0</pub-id><pub-id pub-id-type="pmid">36097221</pub-id><pub-id pub-id-type="pmcid">PMC9509487</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Awasthi</surname><given-names>R</given-names></name><etal/></person-group><article-title>Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL</article-title><source>Blood Adv.</source><year>2020</year><volume>4</volume><fpage>560</fpage><lpage>572</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2019000525</pub-id><pub-id pub-id-type="pmid">32045475</pub-id><pub-id pub-id-type="pmcid">PMC7013261</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Locke</surname><given-names>FL</given-names></name><etal/></person-group><article-title>Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma</article-title><source>Blood Adv.</source><year>2020</year><volume>4</volume><fpage>4898</fpage><lpage>4911</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2020002394</pub-id><pub-id pub-id-type="pmid">33035333</pub-id><pub-id pub-id-type="pmcid">PMC7556133</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chong</surname><given-names>EA</given-names></name><etal/></person-group><article-title>CAR T cell viability release testing and clinical outcomes: is there a lower limit?</article-title><source>Blood</source><year>2019</year><volume>134</volume><fpage>1873</fpage><lpage>1875</lpage><pub-id pub-id-type="doi">10.1182/blood.2019002258</pub-id><pub-id pub-id-type="pmid">31554634</pub-id><pub-id pub-id-type="pmcid">PMC6872962</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Porter</surname><given-names>D</given-names></name><name name-style="western"><surname>Levine</surname><given-names>B</given-names></name><name name-style="western"><surname>Kalos</surname><given-names>M</given-names></name><name name-style="western"><surname>Adam</surname><given-names>B</given-names></name><name name-style="western"><surname>June</surname><given-names>C</given-names></name></person-group><article-title>Chimeric antigen receptor&#8211;modified T cells in chronic lymphoid leukemia</article-title><source>N. Engl. J. Med.</source><year>2011</year><volume>365</volume><fpage>725</fpage><lpage>733</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1103849</pub-id><pub-id pub-id-type="pmid">21830940</pub-id><pub-id pub-id-type="pmcid">PMC3387277</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finney</surname><given-names>OC</given-names></name><etal/></person-group><article-title>CD19 CAR T cell product and disease attributes predict leukemia remission durability</article-title><source>J. Clin. Invest.</source><year>2019</year><volume>129</volume><fpage>2123</fpage><lpage>2132</lpage><pub-id pub-id-type="doi">10.1172/JCI125423</pub-id><pub-id pub-id-type="pmid">30860496</pub-id><pub-id pub-id-type="pmcid">PMC6486329</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fraietta</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia</article-title><source>Nat. Med</source><year>2018</year><volume>24</volume><fpage>563</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1038/s41591-018-0010-1</pub-id><pub-id pub-id-type="pmid">29713085</pub-id><pub-id pub-id-type="pmcid">PMC6117613</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirouac</surname><given-names>DC</given-names></name><etal/></person-group><article-title>Deconvolution of clinical variance in CAR-T cell pharmacology and response</article-title><source>Nat. Biotechnol.</source><year>2023</year><volume>41</volume><fpage>1606</fpage><lpage>1617</lpage><pub-id pub-id-type="doi">10.1038/s41587-023-01687-x</pub-id><pub-id pub-id-type="pmid">36849828</pub-id><pub-id pub-id-type="pmcid">PMC10635825</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rossi</surname><given-names>J</given-names></name><etal/></person-group><article-title>Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL</article-title><source>Blood</source><year>2018</year><volume>132</volume><fpage>804</fpage><lpage>814</lpage><pub-id pub-id-type="doi">10.1182/blood-2018-01-828343</pub-id><pub-id pub-id-type="pmid">29895668</pub-id><pub-id pub-id-type="pmcid">PMC6107882</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bai</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL</article-title><source>Sci. Adv.</source><year>2022</year><volume>8</volume><fpage>eabj2820</fpage><pub-id pub-id-type="doi">10.1126/sciadv.abj2820</pub-id><pub-id pub-id-type="pmid">35675405</pub-id><pub-id pub-id-type="pmcid">PMC9177075</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas</article-title><source>Nat. Med.</source><year>2020</year><volume>26</volume><fpage>1878</fpage><lpage>1887</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-1061-7</pub-id><pub-id pub-id-type="pmid">33020644</pub-id><pub-id pub-id-type="pmcid">PMC8446909</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><etal/></person-group><article-title>A single-cell atlas of CD19 chimeric antigen receptor T cells</article-title><source>Cancer Cell</source><year>2023</year><volume>41</volume><fpage>1835</fpage><lpage>1837</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2023.08.015</pub-id><pub-id pub-id-type="pmid">37738975</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eftimie</surname><given-names>R</given-names></name><name name-style="western"><surname>Bramson</surname><given-names>JL</given-names></name><name name-style="western"><surname>Earn</surname><given-names>DJD</given-names></name></person-group><article-title>Interactions between the immune system and cancer: a brief review of non-spatial mathematical models</article-title><source>B Math. Biol.</source><year>2011</year><volume>73</volume><fpage>2</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1007/s11538-010-9526-3</pub-id><pub-id pub-id-type="pmid">20225137</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mueller-Schoell</surname><given-names>A</given-names></name><etal/></person-group><article-title>Early Survival Prediction Framework in CD19-Specific CAR-T cell immunotherapy using a quantitative systems pharmacology model</article-title><source>Cancers</source><year>2021</year><volume>13</volume><fpage>2782</fpage><pub-id pub-id-type="doi">10.3390/cancers13112782</pub-id><pub-id pub-id-type="pmid">34205020</pub-id><pub-id pub-id-type="pmcid">PMC8199881</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hardiansyah</surname><given-names>D</given-names></name><name name-style="western"><surname>Ng</surname><given-names>CM</given-names></name></person-group><article-title>Quantitative systems pharmacology model of chimeric antigen receptor T&#8208;cell therapy</article-title><source>Clin. Transl. Sci.</source><year>2019</year><volume>12</volume><fpage>343</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.1111/cts.12636</pub-id><pub-id pub-id-type="pmid">30990958</pub-id><pub-id pub-id-type="pmcid">PMC6662387</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sar&#233;n</surname><given-names>T</given-names></name><etal/></person-group><article-title>Single-cell RNA analysis reveals cell-intrinsic functions of CAR-T cells correlating with response in a phase II study of lymphoma patients</article-title><source>Clin. Cancer Res.</source><year>2023</year><volume>29</volume><fpage>4139</fpage><lpage>4152</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-23-0178</pub-id><pub-id pub-id-type="pmid">37540566</pub-id><pub-id pub-id-type="pmcid">PMC10570681</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Graham</surname><given-names>CE</given-names></name><etal/></person-group><article-title>Gene-edited healthy donor CAR T cells show superior anti-tumour activity compared to CAR T cells derived from patients with lymphoma in an in vivo model of high-grade lymphoma</article-title><source>Leukemia</source><year>2021</year><volume>35</volume><fpage>3581</fpage><lpage>3584</lpage><pub-id pub-id-type="doi">10.1038/s41375-021-01324-z</pub-id><pub-id pub-id-type="pmid">34145373</pub-id><pub-id pub-id-type="pmcid">PMC8632681</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>DKY</given-names></name><etal/></person-group><article-title>Enhancing CAR-T cell functionality in a patient-specific manner</article-title><source>Nat. Commun.</source><year>2023</year><volume>14</volume><fpage>506</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-36126-7</pub-id><pub-id pub-id-type="pmid">36720856</pub-id><pub-id pub-id-type="pmcid">PMC9889707</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vlachonikola</surname><given-names>E</given-names></name><name name-style="western"><surname>Stamatopoulos</surname><given-names>K</given-names></name><name name-style="western"><surname>Chatzidimitriou</surname><given-names>A</given-names></name></person-group><article-title>T cells in chronic lymphocytic leukemia: a two-edged sword</article-title><source>Front Immunol.</source><year>2021</year><volume>11</volume><fpage>612244</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.612244</pub-id><pub-id pub-id-type="pmid">33552073</pub-id><pub-id pub-id-type="pmcid">PMC7857025</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meyran</surname><given-names>D</given-names></name><etal/></person-group><article-title>TSTEM-like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models</article-title><source>Sci. Transl. Med.</source><year>2023</year><volume>15</volume><fpage>eabk1900</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.abk1900</pub-id><pub-id pub-id-type="pmid">37018415</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dickinson</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>A novel autologous CAR-T Therapy, YTB323, with preserved T-cell stemness shows enhanced CAR T-cell efficacy in preclinical and early clinical development</article-title><source>Cancer Discov.</source><year>2023</year><volume>13</volume><fpage>1982</fpage><lpage>1997</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-22-1276</pub-id><pub-id pub-id-type="pmid">37249512</pub-id><pub-id pub-id-type="pmcid">PMC10481129</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khot</surname><given-names>A</given-names></name><name name-style="western"><surname>Satoko</surname><given-names>M</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>VA</given-names></name><name name-style="western"><surname>Koya</surname><given-names>RC</given-names></name><name name-style="western"><surname>Shah</surname><given-names>DK</given-names></name></person-group><article-title>Measurement and quantitative characterization of whole-body pharmacokinetics of exogenously administered T cells in mice</article-title><source>J. Pharm. Exp. Ther.</source><year>2019</year><volume>368</volume><fpage>jpet.118.252858</fpage><pub-id pub-id-type="doi">10.1124/jpet.118.252858</pub-id><pub-id pub-id-type="pmcid">PMC6382992</pub-id><pub-id pub-id-type="pmid">30622170</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maria</surname><given-names>NSS</given-names></name><etal/></person-group><article-title>Spatio-temporal biodistribution of 89Zr-oxine labeled huLym-1-A-BB3z-CAR T-cells by PET imaging in a preclinical tumor model</article-title><source>Sci. Rep.-UK</source><year>2021</year><volume>11</volume><fpage>15077</fpage><pub-id pub-id-type="doi">10.1038/s41598-021-94490-0</pub-id><pub-id pub-id-type="pmcid">PMC8302724</pub-id><pub-id pub-id-type="pmid">34302002</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cazaux</surname><given-names>M</given-names></name><etal/></person-group><article-title>Single-cell imaging of CAR T cell activity in vivo reveals extensive functional and anatomical heterogeneity</article-title><source>J. Exp. Med.</source><year>2019</year><volume>216</volume><fpage>1038</fpage><lpage>1049</lpage><pub-id pub-id-type="doi">10.1084/jem.20182375</pub-id><pub-id pub-id-type="pmid">30936262</pub-id><pub-id pub-id-type="pmcid">PMC6504219</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>LV</given-names></name><name name-style="western"><surname>Gaffney</surname><given-names>EA</given-names></name><name name-style="western"><surname>Ager</surname><given-names>A</given-names></name><name name-style="western"><surname>Wagg</surname><given-names>J</given-names></name><name name-style="western"><surname>Coles</surname><given-names>MC</given-names></name></person-group><article-title>Quantifying the limits of CAR T-cell delivery in mice and men</article-title><source>J. R. Soc. Interface</source><year>2021</year><volume>18</volume><fpage>20201013</fpage><pub-id pub-id-type="doi">10.1098/rsif.2020.1013</pub-id><pub-id pub-id-type="pmid">33653113</pub-id><pub-id pub-id-type="pmcid">PMC8086861</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skovgard</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Imaging CAR T-cell kinetics in solid tumors: Translational implications</article-title><source>Mol. Ther. - Oncolyt.</source><year>2021</year><volume>22</volume><fpage>355</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1016/j.omto.2021.06.006</pub-id><pub-id pub-id-type="pmcid">PMC8426175</pub-id><pub-id pub-id-type="pmid">34553024</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Albelda</surname><given-names>SM</given-names></name></person-group><article-title>CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn</article-title><source>Nat. Rev. Clin. Oncol.</source><year>2024</year><volume>21</volume><fpage>47</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1038/s41571-023-00832-4</pub-id><pub-id pub-id-type="pmid">37904019</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Chen</surname><given-names>LC</given-names></name><name name-style="western"><surname>Chen</surname><given-names>YY</given-names></name></person-group><article-title>Navigating CAR-T cells through the solid-tumour microenvironment</article-title><source>Nat. Rev. Drug Discov.</source><year>2021</year><volume>20</volume><fpage>531</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1038/s41573-021-00189-2</pub-id><pub-id pub-id-type="pmid">33972771</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amini</surname><given-names>L</given-names></name><etal/></person-group><article-title>Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion</article-title><source>Nat. Rev. Clin. Oncol.</source><year>2022</year><volume>19</volume><fpage>342</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.1038/s41571-022-00607-3</pub-id><pub-id pub-id-type="pmid">35318469</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirayama</surname><given-names>AV</given-names></name><etal/></person-group><article-title>The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells</article-title><source>Blood</source><year>2019</year><volume>133</volume><fpage>1876</fpage><lpage>1887</lpage><pub-id pub-id-type="doi">10.1182/blood-2018-11-887067</pub-id><pub-id pub-id-type="pmid">30782611</pub-id><pub-id pub-id-type="pmcid">PMC6484391</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turtle</surname><given-names>CJ</given-names></name><etal/></person-group><article-title>Immunotherapy of non-Hodgkin&#8217;s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor&#8211;modified T cells</article-title><source>Sci. Transl. Med</source><year>2016</year><volume>8</volume><fpage>355ra116</fpage><lpage>355ra116</lpage><pub-id pub-id-type="doi">10.1126/scitranslmed.aaf8621</pub-id><pub-id pub-id-type="pmid">27605551</pub-id><pub-id pub-id-type="pmcid">PMC5045301</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kimmel</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Locke</surname><given-names>FL</given-names></name><name name-style="western"><surname>Altrock</surname><given-names>PM</given-names></name></person-group><article-title>The roles of T cell competition and stochastic extinction events in chimeric antigen receptor T cell therapy</article-title><source>Proc. R. Soc. B</source><year>2021</year><volume>288</volume><fpage>20210229</fpage><pub-id pub-id-type="doi">10.1098/rspb.2021.0229</pub-id><pub-id pub-id-type="pmid">33757357</pub-id><pub-id pub-id-type="pmcid">PMC8059581</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scordo</surname><given-names>M</given-names></name><etal/></person-group><article-title>Identifying an Optimal Fludarabine exposure for improved outcomes after CD19 CAR T cell therapy for aggressive B-NHL</article-title><source>Blood Adv.</source><year>2023</year><volume>7</volume><fpage>5579</fpage><lpage>5585</lpage><pub-id pub-id-type="doi">10.1182/bloodadvances.2023010302</pub-id><pub-id pub-id-type="pmid">37522731</pub-id><pub-id pub-id-type="pmcid">PMC10514205</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dupouy</surname><given-names>S</given-names></name><etal/></person-group><article-title>Clinical pharmacology and determinants of response to UCART19, an allogeneic anti-CD19 CAR-T Cell product, in adult B-cell acute lymphoblastic leukemia</article-title><source>Cancer Res Commun.</source><year>2022</year><volume>2</volume><fpage>1520</fpage><lpage>1531</lpage><pub-id pub-id-type="doi">10.1158/2767-9764.CRC-22-0175</pub-id><pub-id pub-id-type="pmid">36970059</pub-id><pub-id pub-id-type="pmcid">PMC10035397</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tully</surname><given-names>S</given-names></name><etal/></person-group><article-title>Impact of increasing wait times on overall mortality of chimeric antigen receptor T-cell therapy in large B-cell lymphoma: a discrete event simulation model</article-title><source>JCO Clin. Cancer Inform.</source><year>2019</year><volume>3</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1200/CCI.19.00086</pub-id><pub-id pub-id-type="pmid">31644324</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Depil</surname><given-names>S</given-names></name><name name-style="western"><surname>Duchateau</surname><given-names>P</given-names></name><name name-style="western"><surname>Grupp</surname><given-names>SA</given-names></name><name name-style="western"><surname>Mufti</surname><given-names>G</given-names></name><name name-style="western"><surname>Poirot</surname><given-names>L</given-names></name></person-group><article-title>&#8216;Off-the-shelf&#8217; allogeneic CAR T cells: development and challenges</article-title><source>Nat. Rev. Drug Discov.</source><year>2020</year><volume>19</volume><fpage>185</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1038/s41573-019-0051-2</pub-id><pub-id pub-id-type="pmid">31900462</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wagner</surname><given-names>DL</given-names></name><etal/></person-group><article-title>Immunogenicity of CAR T cells in cancer therapy</article-title><source>Nat. Rev. Clin. Oncol.</source><year>2021</year><volume>18</volume><fpage>379</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.1038/s41571-021-00476-2</pub-id><pub-id pub-id-type="pmid">33633361</pub-id><pub-id pub-id-type="pmcid">PMC8923136</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benjamin</surname><given-names>R</given-names></name><etal/></person-group><article-title>UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial</article-title><source>Lancet Haematol.</source><year>2022</year><volume>9</volume><fpage>e833</fpage><lpage>e843</lpage><pub-id pub-id-type="doi">10.1016/S2352-3026(22)00245-9</pub-id><pub-id pub-id-type="pmid">36228643</pub-id><pub-id pub-id-type="pmcid">PMC11575699</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Derippe</surname><given-names>T</given-names></name><etal/></person-group><article-title>Mechanistic modeling of the interplay between host immune system, interleukin 7 and UCART19 allogeneic CAR-T cells in adult B-cell acute lymphoblastic leukemia</article-title><source>Cancer Res. Commun.</source><year>2022</year><volume>2</volume><fpage>1532</fpage><lpage>1544</lpage><pub-id pub-id-type="doi">10.1158/2767-9764.CRC-22-0176</pub-id><pub-id pub-id-type="pmid">36970053</pub-id><pub-id pub-id-type="pmcid">PMC10036133</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>3D-organoid culture supports differentiation of human CAR+ iPSCs into highly functional CAR T cells</article-title><source>Cell Stem Cell</source><year>2022</year><volume>29</volume><fpage>515</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2022.02.009</pub-id><pub-id pub-id-type="pmid">35278370</pub-id><pub-id pub-id-type="pmcid">PMC9119152</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iriguchi</surname><given-names>S</given-names></name><etal/></person-group><article-title>A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>430</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-20658-3</pub-id><pub-id pub-id-type="pmid">33462228</pub-id><pub-id pub-id-type="pmcid">PMC7814014</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montel-Hagen</surname><given-names>A</given-names></name><etal/></person-group><article-title>Organoid-induced differentiation of conventional T cells from human Pluripotent stem cells</article-title><source>Cell Stem Cell</source><year>2019</year><volume>24</volume><fpage>376</fpage><lpage>389.e8</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2018.12.011</pub-id><pub-id pub-id-type="pmid">30661959</pub-id><pub-id pub-id-type="pmcid">PMC6687310</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trotman-Grant</surname><given-names>AC</given-names></name><etal/></person-group><article-title>DL4-&#956;beads induce T cell lineage differentiation from stem cells in a stromal cell-free system</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>5023</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-25245-8</pub-id><pub-id pub-id-type="pmid">34408144</pub-id><pub-id pub-id-type="pmcid">PMC8373879</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shukla</surname><given-names>S</given-names></name><etal/></person-group><article-title>Progenitor T-cell differentiation from hematopoietic stem cells using Delta-like-4 and VCAM-1</article-title><source>Nat. Methods</source><year>2017</year><volume>14</volume><fpage>531</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4258</pub-id><pub-id pub-id-type="pmid">28394335</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mehta</surname><given-names>A</given-names></name><etal/></person-group><article-title>Interim Phase I Clinical Data of FT819-101, a Study of the First-Ever, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies</article-title><source>Blood</source><year>2022</year><volume>140</volume><fpage>4577</fpage><lpage>4578</lpage><pub-id pub-id-type="doi">10.1182/blood-2022-167194</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Cellular networks controlling T cell persistence in adoptive cell therapy</article-title><source>Nat. Rev. Immunol.</source><year>2021</year><volume>21</volume><fpage>769</fpage><lpage>784</lpage><pub-id pub-id-type="doi">10.1038/s41577-021-00539-6</pub-id><pub-id pub-id-type="pmid">33879873</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bailey</surname><given-names>SR</given-names></name><name name-style="western"><surname>Maus</surname><given-names>MV</given-names></name></person-group><article-title>Gene editing for immune cell therapies</article-title><source>Nat. Biotechnol.</source><year>2019</year><volume>37</volume><fpage>1425</fpage><lpage>1434</lpage><pub-id pub-id-type="doi">10.1038/s41587-019-0137-8</pub-id><pub-id pub-id-type="pmid">31160723</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bradshaw</surname><given-names>EL</given-names></name><etal/></person-group><article-title>Applications of quantitative systems pharmacology in model&#8208;informed drug discovery: perspective on impact and opportunities</article-title><source>Cpt Pharmacomet. Syst. Pharm.</source><year>2019</year><volume>8</volume><fpage>777</fpage><lpage>791</lpage><pub-id pub-id-type="doi">10.1002/psp4.12463</pub-id><pub-id pub-id-type="pmcid">PMC6875708</pub-id><pub-id pub-id-type="pmid">31535440</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lalonde</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Model&#8208;based drug development</article-title><source>Clin. Pharmacol. Ther.</source><year>2007</year><volume>82</volume><fpage>21</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1038/sj.clpt.6100235</pub-id><pub-id pub-id-type="pmid">17522597</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirouac</surname><given-names>DC</given-names></name></person-group><article-title>Open models for clinical pharmacology</article-title><source>Clin. Pharmacol. Ther.</source><year>2020</year><volume>107</volume><fpage>700</fpage><lpage>702</lpage><pub-id pub-id-type="doi">10.1002/cpt.1738</pub-id><pub-id pub-id-type="pmid">31983060</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scannell</surname><given-names>JW</given-names></name><etal/></person-group><article-title>Predictive validity in drug discovery: what it is, why it matters and how to improve it</article-title><source>Nat. Rev. Drug. Discov.</source><year>2022</year><volume>21</volume><fpage>915</fpage><lpage>931</lpage><pub-id pub-id-type="doi">10.1038/s41573-022-00552-x</pub-id><pub-id pub-id-type="pmid">36195754</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kiesgen</surname><given-names>S</given-names></name><name name-style="western"><surname>Messinger</surname><given-names>JC</given-names></name><name name-style="western"><surname>Chintala</surname><given-names>NK</given-names></name><name name-style="western"><surname>Tano</surname><given-names>Z</given-names></name><name name-style="western"><surname>Adusumilli</surname><given-names>PS</given-names></name></person-group><article-title>Comparative analysis of assays to measure CAR T-cell-mediated cytotoxicity</article-title><source>Nat. Protoc.</source><year>2021</year><volume>16</volume><fpage>1331</fpage><lpage>1342</lpage><pub-id pub-id-type="doi">10.1038/s41596-020-00467-0</pub-id><pub-id pub-id-type="pmid">33589826</pub-id><pub-id pub-id-type="pmcid">PMC8064272</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hafner</surname><given-names>M</given-names></name><name name-style="western"><surname>Niepel</surname><given-names>M</given-names></name><name name-style="western"><surname>Chung</surname><given-names>M</given-names></name><name name-style="western"><surname>Sorger</surname><given-names>PK</given-names></name></person-group><article-title>Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs</article-title><source>Nat. Methods</source><year>2016</year><volume>13</volume><fpage>521</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1038/nmeth.3853</pub-id><pub-id pub-id-type="pmid">27135972</pub-id><pub-id pub-id-type="pmcid">PMC4887336</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sahoo</surname><given-names>P</given-names></name><etal/></person-group><article-title>Mathematical deconvolution of CAR T-cell proliferation and exhaustion from real-time killing assay data</article-title><source>J. R. Soc. Interface</source><year>2020</year><volume>17</volume><fpage>20190734</fpage><pub-id pub-id-type="doi">10.1098/rsif.2019.0734</pub-id><pub-id pub-id-type="pmid">31937234</pub-id><pub-id pub-id-type="pmcid">PMC7014796</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>AP</given-names></name><etal/></person-group><article-title>Bench&#8208;to&#8208;bedside translation of chimeric antigen receptor (CAR) T cells using a multiscale systems pharmacokinetic&#8208;pharmacodynamic model: A case study with anti&#8208;BCMA CAR&#8208;T</article-title><source>CPT Pharmacomet. Syst. Pharm.</source><year>2021</year><volume>10</volume><fpage>362</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1002/psp4.12598</pub-id><pub-id pub-id-type="pmcid">PMC8099446</pub-id><pub-id pub-id-type="pmid">33565700</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Castellanos-Rueda</surname><given-names>R</given-names></name><etal/></person-group><article-title>speedingCARs: accelerating the engineering of CAR T cells by signaling domain shuffling and single-cell sequencing</article-title><source>Nat. Commun.</source><year>2022</year><volume>13</volume><fpage>6555</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-34141-8</pub-id><pub-id pub-id-type="pmid">36323661</pub-id><pub-id pub-id-type="pmcid">PMC9630321</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daniels</surname><given-names>KG</given-names></name><etal/></person-group><article-title>Decoding CAR T cell phenotype using combinatorial signaling motif libraries and machine learning</article-title><source>Science</source><year>2022</year><volume>378</volume><fpage>1194</fpage><lpage>1200</lpage><pub-id pub-id-type="doi">10.1126/science.abq0225</pub-id><pub-id pub-id-type="pmid">36480602</pub-id><pub-id pub-id-type="pmcid">PMC10026561</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dai</surname><given-names>X</given-names></name><etal/></person-group><article-title>Massively parallel knock-in engineering of human T cells</article-title><source>Nat. Biotechnol.</source><year>2023</year><volume>41</volume><fpage>1239</fpage><lpage>1255</lpage><pub-id pub-id-type="doi">10.1038/s41587-022-01639-x</pub-id><pub-id pub-id-type="pmid">36702900</pub-id><pub-id pub-id-type="pmcid">PMC11260498</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nilsson</surname><given-names>A</given-names></name><name name-style="western"><surname>Peters</surname><given-names>JM</given-names></name><name name-style="western"><surname>Meimetis</surname><given-names>N</given-names></name><name name-style="western"><surname>Bryson</surname><given-names>B</given-names></name><name name-style="western"><surname>Lauffenburger</surname><given-names>DA</given-names></name></person-group><article-title>Artificial neural networks enable genome-scale simulations of intracellular signaling</article-title><source>Nat. Commun.</source><year>2022</year><volume>13</volume><fpage>3069</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-30684-y</pub-id><pub-id pub-id-type="pmid">35654811</pub-id><pub-id pub-id-type="pmcid">PMC9163072</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>B</given-names></name><etal/></person-group><article-title>CellBox: Interpretable machine learning for perturbation biology with application to the design of cancer combination therapy</article-title><source>Cell Syst.</source><year>2021</year><volume>12</volume><fpage>128</fpage><lpage>140.e4</lpage><pub-id pub-id-type="doi">10.1016/j.cels.2020.11.013</pub-id><pub-id pub-id-type="pmid">33373583</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lipsitz</surname><given-names>YY</given-names></name><name name-style="western"><surname>Timmins</surname><given-names>NE</given-names></name><name name-style="western"><surname>Zandstra</surname><given-names>PW</given-names></name></person-group><article-title>Quality cell therapy manufacturing by design</article-title><source>Nat. Biotechnol.</source><year>2016</year><volume>34</volume><fpage>393</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1038/nbt.3525</pub-id><pub-id pub-id-type="pmid">27054995</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><mixed-citation publication-type="other">Plato. <italic toggle="yes">The Republic</italic> (375 BC).</mixed-citation></ref><ref id="CR100"><label>100.</label><mixed-citation publication-type="other">Mehta, A. Interim Phase 1 clinical data of FT-819-101, a study of the first ever, off-the-shelf, iPSC-derived TCR-less CD19 CART therapy for patients with relapsed/refractory B cell malignancies. ASH <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://fatetherapeutics.com/wp-content/uploads/2022/12/2000-FT81989.pdf">https://fatetherapeutics.com/wp-content/uploads/2022/12/2000-FT81989.pdf</ext-link> (2022).</mixed-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kochenderfer</surname><given-names>JN</given-names></name><etal/></person-group><article-title>Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high Serum Interleukin-15 Levels</article-title><source>J. Clin. Oncol.</source><year>2017</year><volume>35</volume><fpage>JCO.2016.71.302</fpage><pub-id pub-id-type="doi">10.1200/JCO.2016.71.3024</pub-id><pub-id pub-id-type="pmcid">PMC5455597</pub-id><pub-id pub-id-type="pmid">28291388</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><mixed-citation publication-type="other">Stein, A. The cellular kinetics and anti-tumor dynamics of Kymriah. in <italic toggle="yes">AcoP10</italic><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://drive.google.com/file/d/1Uz69ZXIVLp_9RPaBBhex7fLxRPk7og8e/view">https://drive.google.com/file/d/1Uz69ZXIVLp_9RPaBBhex7fLxRPk7og8e/view</ext-link> (2019).</mixed-citation></ref><ref id="CR103"><label>103.</label><mixed-citation publication-type="other">Wallet, M. et al. Compositions and methods for generating Gamma-Delta T cells from induced pluripotent stem cells. USPTO #US20220333073A1. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://patents.google.com/patent/US20220333073A1/en">https://patents.google.com/patent/US20220333073A1/en</ext-link> (2022).</mixed-citation></ref></ref-list></back></article></pmc-articleset>